

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C12Q 1/68, C07H 21/04, C12N 15/00</b>		A1	(11) International Publication Number: <b>WO 00/32816</b> (43) International Publication Date: <b>8 June 2000 (08.06.00)</b>
(21) International Application Number: <b>PCT/US99/13624</b> (22) International Filing Date: <b>16 June 1999 (16.06.99)</b> (30) Priority Data: <b>09/205,204                      3 December 1998 (03.12.98)                      US</b> (71) Applicant (for all designated States except US): <b>ISIS PHARMACEUTICALS, INC. [US/US]; Carlsbad Research Center, 2292 Faraday Avenue, Carlsbad, CA 92008 (US).</b> (72) Inventors; and (75) Inventors/Applicants (for US only): <b>BENNETT, C., Frank [US/US]; 1347 Cassins Street, Carlsbad, CA 92009 (US). ACKERMANN, Elizabeth, A. [US/US]; 519 Santa Victoria, Solana Beach, CA 92075 (US). COWSERT, Lex, M. [US/US]; 3008 Newshire Street, Carlsbad, CA 92008 (US).</b> (74) Agents: <b>LICATA, Jane, Massey et al.; Law Offices of Jane Massey Licata, 66 E. Main Street, Marlton, NJ 08053 (US).</b>		(81) Designated States: <b>AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</b>  <b>Published</b> <i>With international search report.</i>	
(54) Title: <b>ANTISENSE MODULATION OF CELLULAR INHIBITOR OF APOPTOSIS-1 EXPRESSION</b>			
(57) Abstract <p>Antisense compounds, compositions and methods are provided for modulating the expression of Cellular Inhibitor of Apoptosis-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Cellular Inhibitor of Apoptosis-1. Methods of using these compounds for modulation of Cellular Inhibitor of Apoptosis-1 expression and for treatment of diseases associated with expression of Cellular Inhibitor of Apoptosis-1 are provided.</p>			

BEST AVAILABLE COPY

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

**ANTISENSE MODULATION OF CELLULAR  
INHIBITOR OF APOPTOSIS-1 EXPRESSION**

**FIELD OF THE INVENTION**

The present invention provides compositions and  
5 methods for modulating the expression of Cellular Inhibitor  
of Apoptosis-1. In particular, this invention relates to  
antisense compounds, particularly oligonucleotides,  
specifically hybridizable with nucleic acids encoding human  
Cellular Inhibitor of Apoptosis-1. Such oligonucleotides  
10 have been shown to modulate the expression of Cellular  
Inhibitor of Apoptosis-1.

**BACKGROUND OF THE INVENTION**

Apoptosis, or programmed cell death, is a naturally  
occurring process that has been strongly conserved during  
15 evolution to prevent uncontrolled cell proliferation. This  
form of cell suicide plays a crucial role in the development  
and maintenance of multicellular organisms by eliminating  
superfluous or unwanted cells. However, if this process goes  
awry, excessive apoptosis results in cell loss and  
20 degenerative disorders, while insufficient apoptosis  
contributes to the development of cancer, autoimmune disorders  
and viral infections (Thompson, *Science*, **1995**, 267, 1456-  
1462).

Although several stimuli can induce apoptosis, little is  
25 known about the intermediate signaling events, including  
inhibition, that connect the apoptotic signal to a common cell  
death pathway conserved across many species. Recently, a  
family of apoptosis inhibitor proteins homologous to those  
produced by viruses has been identified in humans.

30 Cellular Inhibitor of Apoptosis-1 (also known as c-IAP-1,  
apoptosis inhibitor 1, API-1, hIAP-2, and MIHB) is a member  
of the inhibitor of apoptosis (IAP) family of anti-apoptotic  
proteins which interfere with the transmission of  
intracellular death signals. It was first cloned and

characterized as a component of the TNFR2-TRAF signaling pathway (Rothe et al., *Cell*, **1994**, 78, 681-692) and was shown to be recruited to the cytoplasmic domain of TNFR2 in association with a TRAF2-TRAF1 heterocomplex (Rothe et al., *Cell*, **1995**, 83, 1243-1252). Later it was identified as a factor that could inhibit apoptosis caused by the overexpression of interleukin 1 beta converting enzyme (ICE) or caspase-1, a protease required for apoptosis in mammals (Uren et al., *Proc. Natl. Acad. Sci. U S A*, **1996**, 93, 4974-4978). Subsequently, it has been shown that Cellular Inhibitor of Apoptosis-1 inhibits other cell death proteases, namely caspase-3, caspase-7 and caspase-8 (Deveraux et al., *Embo J.*, **1998**, 17, 2215-2223; Roy et al., *Embo J.*, **1997**, 16, 6914-6925; Wang et al., *Science*, **1998**, 281, 1680-1683). Furthermore, Cellular Inhibitor of Apoptosis-1 has been shown to play a role in TNFR1 signaling pathways which are independent of the TNFR2 pathways previously identified (Shu et al., *Proc. Natl. Acad. Sci. U S A*, **1996**, 93, 13973-13978).

Cellular Inhibitor of Apoptosis-1 mRNA expression is most abundant in thymus, testis and ovary (Rothe et al., *Cell*, **1995**, 83, 1243-1252) and has been shown to be regulated during follicular development of rat granulosa and theca cells suggesting a role for Cellular Inhibitor of Apoptosis-1 in the control of stage-specific follicular atresia (Li et al., *Endocrinology*, **1998**, 139, 1321-1328).

Currently, there are no known therapeutic agents which effectively inhibit the synthesis of Cellular Inhibitor of Apoptosis-1.

To date, strategies aimed at inhibiting Cellular Inhibitor of Apoptosis-1 function have involved the use of molecules that block upstream entities including the TRAF2-TRAF1 heterocomplex and components of the TNF signaling cascade.

However, these strategies are untested as therapeutic

protocols as well as being non-specific to Cellular Inhibitor of Apoptosis-1, as many divergent pathways arise from TNF signaling. Consequently, there remains a long felt need for additional agents capable of effectively  
5 inhibiting Cellular Inhibitor of Apoptosis-1 function. It is therefore believed that antisense oligonucleotides will provide a promising new pharmaceutical tool for the effective and specific modulation of Cellular Inhibitor of Apoptosis-1 expression.

#### 10 SUMMARY OF THE INVENTION

The present invention is directed to antisense compounds, particularly oligonucleotides, which are targeted to a nucleic acid encoding Cellular Inhibitor of Apoptosis-1, and which modulate the expression of Cellular  
15 Inhibitor of Apoptosis-1. Pharmaceutical and other compositions comprising the antisense compounds of the invention are also provided. Further provided are methods of modulating the expression of Cellular Inhibitor of Apoptosis-1 in cells or tissues comprising contacting said  
20 cells or tissues with one or more of the antisense compounds or compositions of the invention. Further provided are methods of treating an animal, particularly a human, suspected of having or being prone to a disease or condition associated with expression of Cellular Inhibitor  
25 of Apoptosis-1 by administering a therapeutically or prophylactically effective amount of one or more of the antisense compounds or compositions of the invention.

#### DETAILED DESCRIPTION OF THE INVENTION

The present invention employs oligomeric antisense  
30 compounds, particularly oligonucleotides, for use in modulating the function of nucleic acid molecules encoding Cellular Inhibitor of Apoptosis-1, ultimately modulating the amount of Cellular Inhibitor of Apoptosis-1 produced. This is accomplished by providing antisense compounds which  
35 specifically hybridize with one or more nucleic acids

encoding Cellular Inhibitor of Apoptosis-1. As used herein, the terms "target nucleic acid" and "nucleic acid encoding Cellular Inhibitor of Apoptosis-1" encompass DNA encoding Cellular Inhibitor of Apoptosis-1, RNA (including pre-mRNA and mRNA) transcribed from such DNA, and also cDNA derived from such RNA. The specific hybridization of an oligomeric compound with its target nucleic acid interferes with the normal function of the nucleic acid. This modulation of function of a target nucleic acid by compounds which specifically hybridize to it is generally referred to as "antisense". The functions of DNA to be interfered with include replication and transcription. The functions of RNA to be interfered with include all vital functions such as, for example, translocation of the RNA to the site of protein translation, translation of protein from the RNA, splicing of the RNA to yield one or more mRNA species, and catalytic activity which may be engaged in or facilitated by the RNA. The overall effect of such interference with target nucleic acid function is modulation of the expression of Cellular Inhibitor of Apoptosis-1. In the context of the present invention, "modulation" means either an increase (stimulation) or a decrease (inhibition) in the expression of a gene. In the context of the present invention, inhibition is the preferred form of modulation of gene expression and mRNA is a preferred target.

It is preferred to target specific nucleic acids for antisense. "Targeting" an antisense compound to a particular nucleic acid, in the context of this invention, is a multistep process. The process usually begins with the identification of a nucleic acid sequence whose function is to be modulated. This may be, for example, a cellular gene (or mRNA transcribed from the gene) whose expression is associated with a particular disorder or disease state, or a nucleic acid molecule from an

infectious agent. In the present invention, the target is a nucleic acid molecule encoding Cellular Inhibitor of Apoptosis-1. The targeting process also includes determination of a site or sites within this gene for the antisense interaction to occur such that the desired effect, e.g., detection or modulation of expression of the protein, will result. Within the context of the present invention, a preferred intragenic site is the region encompassing the translation initiation or termination codon of the open reading frame (ORF) of the gene. Since, as is known in the art, the translation initiation codon is typically 5'-AUG (in transcribed mRNA molecules; 5'-ATG in the corresponding DNA molecule), the translation initiation codon is also referred to as the "AUG codon," the "start codon" or the "AUG start codon". A minority of genes have a translation initiation codon having the RNA sequence 5'-GUG, 5'-UUG or 5'-CUG, and 5'-AUA, 5'-ACG and 5'-CUG have been shown to function in vivo. Thus, the terms "translation initiation codon" and "start codon" can encompass many codon sequences, even though the initiator amino acid in each instance is typically methionine (in eukaryotes) or formylmethionine (in prokaryotes). It is also known in the art that eukaryotic and prokaryotic genes may have two or more alternative start codons, any one of which may be preferentially utilized for translation initiation in a particular cell type or tissue, or under a particular set of conditions. In the context of the invention, "start codon" and "translation initiation codon" refer to the codon or codons that are used in vivo to initiate translation of an mRNA molecule transcribed from a gene encoding Cellular Inhibitor of Apoptosis-1, regardless of the sequence(s) of such codons.

It is also known in the art that a translation termination codon (or "stop codon") of a gene may have one of three sequences, i.e., 5'-UAA, 5'-UAG and 5'-UGA (the

corresponding DNA sequences are 5'-TAA, 5'-TAG and 5'-TGA, respectively). The terms "start codon region" and "translation initiation codon region" refer to a portion of such an mRNA or gene that encompasses from about 25 to  
5 about 50 contiguous nucleotides in either direction (i.e., 5' or 3') from a translation initiation codon. Similarly, the terms "stop codon region" and "translation termination codon region" refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous  
10 nucleotides in either direction (i.e., 5' or 3') from a translation termination codon.

The open reading frame (ORF) or "coding region," which is known in the art to refer to the region between the translation initiation codon and the translation  
15 termination codon, is also a region which may be targeted effectively. Other target regions include the 5' untranslated region (5'UTR), known in the art to refer to the portion of an mRNA in the 5' direction from the translation initiation codon, and thus including  
20 nucleotides between the 5' cap site and the translation initiation codon of an mRNA or corresponding nucleotides on the gene, and the 3' untranslated region (3'UTR), known in the art to refer to the portion of an mRNA in the 3' direction from the translation termination codon, and thus  
25 including nucleotides between the translation termination codon and 3' end of an mRNA or corresponding nucleotides on the gene. The 5' cap of an mRNA comprises an N7-methylated guanosine residue joined to the 5'-most residue of the mRNA via a 5'-5' triphosphate linkage. The 5' cap region of an  
30 mRNA is considered to include the 5' cap structure itself as well as the first 50 nucleotides adjacent to the cap. The 5' cap region may also be a preferred target region.

Although some eukaryotic mRNA transcripts are directly translated, many contain one or more regions, known as  
35 "introns," which are excised from a transcript before it is



translated. The remaining (and therefore translated) regions are known as "exons" and are spliced together to form a continuous mRNA sequence. mRNA splice sites, i.e., intron-exon junctions, may also be preferred target regions, and are particularly useful in situations where aberrant splicing is implicated in disease, or where an overproduction of a particular mRNA splice product is implicated in disease. Aberrant fusion junctions due to rearrangements or deletions are also preferred targets. It has also been found that introns can also be effective, and therefore preferred, target regions for antisense compounds targeted, for example, to DNA or pre-mRNA.

Once one or more target sites have been identified, oligonucleotides are chosen which are sufficiently complementary to the target, i.e., hybridize sufficiently well and with sufficient specificity, to give the desired effect.

In the context of this invention, "hybridization" means hydrogen bonding, which may be Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding, between complementary nucleoside or nucleotide bases. For example, adenine and thymine are complementary nucleobases which pair through the formation of hydrogen bonds.

"Complementary," as used herein, refers to the capacity for precise pairing between two nucleotides. For example, if a nucleotide at a certain position of an oligonucleotide is capable of hydrogen bonding with a nucleotide at the same position of a DNA or RNA molecule, then the oligonucleotide and the DNA or RNA are considered to be complementary to each other at that position. The oligonucleotide and the DNA or RNA are complementary to each other when a sufficient number of corresponding positions in each molecule are occupied by nucleotides which can hydrogen bond with each other. Thus, "specifically hybridizable" and "complementary" are terms which are used to indicate a

sufficient degree of complementarity or precise pairing such that stable and specific binding occurs between the oligonucleotide and the DNA or RNA target. It is understood in the art that the sequence of an antisense compound need not be 100% complementary to that of its target nucleic acid to be specifically hybridizable. An antisense compound is specifically hybridizable when binding of the compound to the target DNA or RNA molecule interferes with the normal function of the target DNA or RNA to cause a loss of utility, and there is a sufficient degree of complementarity to avoid non-specific binding of the antisense compound to non-target sequences under conditions in which specific binding is desired, i.e., under physiological conditions in the case of in vivo assays or therapeutic treatment, and in the case of in vitro assays, under conditions in which the assays are performed.

Antisense compounds are commonly used as research reagents and diagnostics. For example, antisense oligonucleotides, which are able to inhibit gene expression with exquisite specificity, are often used by those of ordinary skill to elucidate the function of particular genes. Antisense compounds are also used, for example, to distinguish between functions of various members of a biological pathway. Antisense modulation has, therefore, been harnessed for research use.

The specificity and sensitivity of antisense is also harnessed by those of skill in the art for therapeutic uses. Antisense oligonucleotides have been employed as therapeutic moieties in the treatment of disease states in animals and man. Antisense oligonucleotides have been safely and effectively administered to humans and numerous clinical trials are presently underway. It is thus established that oligonucleotides can be useful therapeutic modalities that can be configured to be useful in treatment

regimes for treatment of cells, tissues and animals, especially humans.

In the context of this invention, the term

"oligonucleotide" refers to an oligomer or polymer of  
5 ribonucleic acid (RNA) or deoxyribonucleic acid (DNA) or  
mimetics thereof. This term includes oligonucleotides  
composed of naturally-occurring nucleobases, sugars and  
covalent internucleoside (backbone) linkages as well as  
oligonucleotides having non-naturally-occurring portions  
10 which function similarly. Such modified or substituted  
oligonucleotides are often preferred over native forms  
because of desirable properties such as, for example,  
enhanced cellular uptake, enhanced affinity for nucleic  
acid target and increased stability in the presence of  
15 nucleases.

While antisense oligonucleotides are a preferred form  
of antisense compound, the present invention comprehends  
other oligomeric antisense compounds, including but not  
limited to oligonucleotide mimetics such as are described  
20 below. The antisense compounds in accordance with this  
invention preferably comprise from about 8 to about 30  
nucleobases. Particularly preferred are antisense  
oligonucleotides comprising from about 8 to about 30  
nucleobases (i.e. from about 8 to about 30 linked  
25 nucleosides). As is known in the art, a nucleoside is a  
base-sugar combination. The base portion of the nucleoside  
is normally a heterocyclic base. The two most common  
classes of such heterocyclic bases are the purines and the  
pyrimidines. Nucleotides are nucleosides that further  
30 include a phosphate group covalently linked to the sugar  
portion of the nucleoside. For those nucleosides that  
include a pentofuranosyl sugar, the phosphate group can be  
linked to either the 2', 3' or 5' hydroxyl moiety of the  
sugar. In forming oligonucleotides, the phosphate groups  
35 covalently link adjacent nucleosides to one another to form

a linear polymeric compound. In turn the respective ends of this linear polymeric structure can be further joined to form a circular structure, however, open linear structures are generally preferred. Within the oligonucleotide structure, the phosphate groups are commonly referred to as forming the internucleoside backbone of the oligonucleotide. The normal linkage or backbone of RNA and DNA is a 3' to 5' phosphodiester linkage.

Specific examples of preferred antisense compounds useful in this invention include oligonucleotides containing modified backbones or non-natural internucleoside linkages. As defined in this specification, oligonucleotides having modified backbones include those that retain a phosphorus atom in the backbone and those that do not have a phosphorus atom in the backbone. For the purposes of this specification, and as sometimes referenced in the art, modified oligonucleotides that do not have a phosphorus atom in their internucleoside backbone can also be considered to be oligonucleosides.

Preferred modified oligonucleotide backbones include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3'-5' linkages, 2'-5' linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3'-5' to 5'-3' or 2'-5' to 5'-2'. Various salts, mixed salts and free acid forms are also included.

Representative United States patents that teach the preparation of the above phosphorus-containing linkages

include, but are not limited to, U.S.: 3,687,808;  
4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897;  
5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131;  
5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677;  
5 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111;  
5,563,253; 5,571,799; 5,587,361; and 5,625,050, certain of  
which are commonly owned with this application, and each of  
which is herein incorporated by reference.

Preferred modified oligonucleotide backbones that do  
10 not include a phosphorus atom therein have backbones that  
are formed by short chain alkyl or cycloalkyl  
internucleoside linkages, mixed heteroatom and alkyl or  
cycloalkyl internucleoside linkages, or one or more short  
chain heteroatomic or heterocyclic internucleoside  
15 linkages. These include those having morpholino linkages  
(formed in part from the sugar portion of a nucleoside);  
siloxane backbones; sulfide, sulfoxide and sulfone  
backbones; formacetyl and thioformacetyl backbones;  
methylene formacetyl and thioformacetyl backbones; alkene  
20 containing backbones; sulfamate backbones; methyleneimino  
and methylenehydrazino backbones; sulfonate and sulfonamide  
backbones; amide backbones; and others having mixed N, O, S  
and CH<sub>2</sub> component parts.

Representative United States patents that teach the  
25 preparation of the above oligonucleosides include, but are  
not limited to, U.S.: 5,034,506; 5,166,315; 5,185,444;  
5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564;  
5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677;  
5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289;  
30 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070;  
5,663,312; 5,633,360; 5,677,437; and 5,677,439, certain of  
which are commonly owned with this application, and each of  
which is herein incorporated by reference.

In other preferred oligonucleotide mimetics, both the  
35 sugar and the internucleoside linkage, i.e., the backbone,

of the nucleotide units are replaced with novel groups. The base units are maintained for hybridization with an appropriate nucleic acid target compound. One such oligomeric compound, an oligonucleotide mimetic that has  
5 been shown to have excellent hybridization properties, is referred to as a peptide nucleic acid (PNA). In PNA compounds, the sugar-backbone of an oligonucleotide is replaced with an amide containing backbone, in particular an aminoethylglycine backbone. The nucleobases are  
10 retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone. Representative United States patents that teach the preparation of PNA compounds include, but are not limited to, U.S.: 5,539,082; 5,714,331; and 5,719,262, each of  
15 which is herein incorporated by reference. Further teaching of PNA compounds can be found in Nielsen et al., *Science*, 1991, 254, 1497-1500.

Most preferred embodiments of the invention are oligonucleotides with phosphorothioate backbones and  
20 oligonucleosides with heteroatom backbones, and in particular  $-\text{CH}_2-\text{NH}-\text{O}-\text{CH}_2-$ ,  $-\text{CH}_2-\text{N}(\text{CH}_3)-\text{O}-\text{CH}_2-$  [known as a methylene (methyylimino) or MMI backbone],  $-\text{CH}_2-\text{O}-\text{N}(\text{CH}_3)-\text{CH}_2-$ ,  $-\text{CH}_2-\text{N}(\text{CH}_3)-\text{N}(\text{CH}_3)-\text{CH}_2-$  and  $-\text{O}-\text{N}(\text{CH}_3)-\text{CH}_2-\text{CH}_2-$  [wherein the native phosphodiester backbone is represented as  $-\text{O}-\text{P}-\text{O}-\text{CH}_2-$   
25 ] of the above referenced U.S. patent 5,489,677, and the amide backbones of the above referenced U.S. patent 5,602,240. Also preferred are oligonucleotides having morpholino backbone structures of the above-referenced U.S. patent 5,034,506.

30 Modified oligonucleotides may also contain one or more substituted sugar moieties. Preferred oligonucleotides comprise one of the following at the 2' position: OH; F; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S- or N-alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and  
35 alkynyl may be substituted or unsubstituted  $\text{C}_1$  to  $\text{C}_{10}$  alkyl

or C<sub>2</sub> to C<sub>10</sub> alkenyl and alkynyl. Particularly preferred are O[(CH<sub>2</sub>)<sub>n</sub>O]<sub>m</sub>CH<sub>3</sub>, O(CH<sub>2</sub>)<sub>n</sub>OCH<sub>3</sub>, O(CH<sub>2</sub>)<sub>n</sub>NH<sub>2</sub>, O(CH<sub>2</sub>)<sub>n</sub>CH<sub>3</sub>, O(CH<sub>2</sub>)<sub>n</sub>ONH<sub>2</sub>, and O(CH<sub>2</sub>)<sub>n</sub>ON[(CH<sub>2</sub>)<sub>n</sub>CH<sub>3</sub>]<sub>2</sub>, where n and m are from 1 to about 10. Other preferred oligonucleotides comprise one of the following at the 2' position: C<sub>1</sub> to C<sub>10</sub> lower alkyl, substituted lower alkyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH<sub>3</sub>, OCN, Cl, Br, CN, CF<sub>3</sub>, OCF<sub>3</sub>, SOCH<sub>3</sub>, SO<sub>2</sub>CH<sub>3</sub>, ONO<sub>2</sub>, NO<sub>2</sub>, N<sub>3</sub>, NH<sub>2</sub>, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an oligonucleotide, or a group for improving the pharmacodynamic properties of an oligonucleotide, and other substituents having similar properties. A preferred modification includes 2'-methoxyethoxy (2'-O-CH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub>, also known as 2'-O-(2-methoxyethyl) or 2'-MOE) (Martin et al., *Helv. Chim. Acta*, **1995**, 78, 486-504) i.e., an alkoxyalkoxy group. A further preferred modification includes 2'-dimethylaminoethoxy, i.e., a O(CH<sub>2</sub>)<sub>2</sub>ON(CH<sub>3</sub>)<sub>2</sub> group, also known as 2'-DMAOE, as described in examples hereinbelow.

Other preferred modifications include 2'-methoxy (2'-O-CH<sub>3</sub>), 2'-aminopropoxy (2'-OCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>) and 2'-fluoro (2'-F). Similar modifications may also be made at other positions on the oligonucleotide, particularly the 3' position of the sugar on the 3' terminal nucleotide or in 2'-5' linked oligonucleotides and the 5' position of 5' terminal nucleotide. Oligonucleotides may also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar. Representative United States patents that teach the preparation of such modified sugar structures include, but are not limited to, U.S.:

4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878;  
5,446,137; 5,466,786; 5,514,785; 5,519,134; 5,567,811;  
5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,053;  
5,639,873; 5,646,265; 5,658,873; 5,670,633; and 5,700,920,

certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference in its entirety.

Oligonucleotides may also include nucleobase (often referred to in the art simply as "base") modifications or substitutions. As used herein, "unmodified" or "natural" nucleobases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U). Modified nucleobases include other synthetic and natural nucleobases such as 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 3-deazaadenine. Further nucleobases include those disclosed in United States Patent No. 3,687,808, those disclosed in *The Concise Encyclopedia Of Polymer Science And Engineering*, pages 858-859, Kroschwitz, J.I., ed. John Wiley & Sons, 1990, those disclosed by Englisch et al., *Angewandte Chemie*, International Edition, 1991, 30, 613, and those disclosed by Sanghvi, Y.S., Chapter 15, *Antisense Research and Applications*, pages 289-302, Crooke, S.T. and Lebleu, B. , ed., CRC Press, 1993. Certain of these nucleobases are particularly useful for increasing the binding affinity of the oligomeric compounds of the invention. These include 5-substituted pyrimidines,



6-azapyrimidines and N-2, N-6 and O-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine. 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2°C (Sanghvi, Y.S., Crooke, S.T. and Lebleu, B., eds., *Antisense Research and Applications*, CRC Press, Boca Raton, **1993**, pp. 276-278) and are presently preferred base substitutions, even more particularly when combined with 2'-O-methoxyethyl sugar modifications.

Representative United States patents that teach the preparation of certain of the above noted modified nucleobases as well as other modified nucleobases include, but are not limited to, the above noted U.S. 3,687,808, as well as U.S.: 4,845,205; 5,130,302; 5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121, 5,596,091; 5,614,617; and 5,681,941, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference, and United States patent 5,750,692, which is commonly owned with the instant application and also herein incorporated by reference.

Another modification of the oligonucleotides of the invention involves chemically linking to the oligonucleotide one or more moieties or conjugates which enhance the activity, cellular distribution or cellular uptake of the oligonucleotide. Such moieties include but are not limited to lipid moieties such as a cholesterol moiety (Letsinger et al., *Proc. Natl. Acad. Sci. USA*, **1989**, *86*, 6553-6556), cholic acid (Manoharan et al., *Bioorg. Med. Chem. Lett.*, **1994**, *4*, 1053-1060), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al., *Ann. N.Y. Acad. Sci.*, **1992**, *660*, 306-309; Manoharan et al., *Bioorg. Med. Chem. Lett.*, **1993**, *3*, 2765-2770), a thiocholesterol (Oberhauser et

al., *Nucl. Acids Res.*, **1992**, *20*, 533-538), an aliphatic chain, e.g., dodecandiol or undecyl residues (Saison-Behmoaras et al., *EMBO J.*, **1991**, *10*, 1111-1118; Kabanov et al., *FEBS Lett.*, **1990**, *259*, 327-330; Svinarchuk et al., *Biochimie*, **1993**, *75*, 49-54), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., *Tetrahedron Lett.*, **1995**, *36*, 3651-3654; Shea et al., *Nucl. Acids Res.*, **1990**, *18*, 3777-3783), a polyamine or a polyethylene glycol chain (Manoharan et al., *Nucleosides & Nucleotides*, **1995**, *14*, 969-973), or adamantane acetic acid (Manoharan et al., *Tetrahedron Lett.*, **1995**, *36*, 3651-3654), a palmityl moiety (Mishra et al., *Biochim. Biophys. Acta*, **1995**, *1264*, 229-237), or an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety (Crooke et al., *J. Pharmacol. Exp. Ther.*, **1996**, *277*, 923-937).

Representative United States patents that teach the preparation of such oligonucleotide conjugates include, but are not limited to, U.S.: 4,828,979; 4,948,882; 5,218,105; 5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,578,717; 5,580,731; 5,580,731; 5,591,584; 5,109,124; 5,118,802; 5,138,045; 5,414,077; 5,486,603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779; 4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582; 4,958,013; 5,082,830; 5,112,963; 5,214,136; 5,082,830; 5,112,963; 5,214,136; 5,245,022; 5,254,469; 5,258,506; 5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241; 5,391,723; 5,416,203; 5,451,463; 5,510,475; 5,512,667; 5,514,785; 5,565,552; 5,567,810; 5,574,142; 5,585,481; 5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599,928 and 5,688,941, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference.

It is not necessary for all positions in a given

-17-

compound to be uniformly modified, and in fact more than one of the aforementioned modifications may be incorporated in a single compound or even at a single nucleoside within an oligonucleotide. The present invention also includes  
5 antisense compounds which are chimeric compounds. "Chimeric" antisense compounds or "chimeras," in the context of this invention, are antisense compounds, particularly oligonucleotides, which contain two or more chemically distinct regions, each made up of at least one  
10 monomer unit, i.e., a nucleotide in the case of an oligonucleotide compound. These oligonucleotides typically contain at least one region wherein the oligonucleotide is modified so as to confer upon the oligonucleotide increased resistance to nuclease degradation, increased cellular  
15 uptake, and/or increased binding affinity for the target nucleic acid. An additional region of the oligonucleotide may serve as a substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids. By way of example, RNase H is a cellular endonuclease which cleaves the RNA strand of an  
20 RNA:DNA duplex. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of oligonucleotide inhibition of gene expression. Consequently, comparable results can often be obtained with shorter oligonucleotides when chimeric  
25 oligonucleotides are used, compared to phosphorothioate deoxyoligonucleotides hybridizing to the same target region. Cleavage of the RNA target can be routinely detected by gel electrophoresis and, if necessary, associated nucleic acid hybridization techniques known in  
30 the art.

Chimeric antisense compounds of the invention may be formed as composite structures of two or more oligonucleotides, modified oligonucleotides, oligonucleosides and/or oligonucleotide mimetics as  
35 described above. Such compounds have also been referred to

in the art as hybrids or gapmers. Representative United States patents that teach the preparation of such hybrid structures include, but are not limited to, U.S.:

5,013,830; 5,149,797; 5,220,007; 5,256,775; 5,366,878;  
5 5,403,711; 5,491,133; 5,565,350; 5,623,065; 5,652,355;  
5,652,356; and 5,700,922, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference in its entirety.

The antisense compounds used in accordance with this  
10 invention may be conveniently and routinely made through the well-known technique of solid phase synthesis. Equipment for such synthesis is sold by several vendors including, for example, Applied Biosystems (Foster City, CA). Any other means for such synthesis known in the art  
15 may additionally or alternatively be employed. It is well known to use similar techniques to prepare oligonucleotides such as the phosphorothioates and alkylated derivatives.

The antisense compounds of the invention are synthesized in vitro and do not include antisense  
20 compositions of biological origin, or genetic vector constructs designed to direct the in vivo synthesis of antisense molecules.

The compounds of the invention may also be admixed, encapsulated, conjugated or otherwise associated with other  
25 molecules, molecule structures or mixtures of compounds, as for example, liposomes, receptor targeted molecules, oral, rectal, topical or other formulations, for assisting in uptake, distribution and/or absorption. Representative United States patents that teach the preparation of such  
30 uptake, distribution and/or absorption assisting formulations include, but are not limited to, U.S.:

5,108,921; 5,354,844; 5,416,016; 5,459,127; 5,521,291;  
5,543,158; 5,547,932; 5,583,020; 5,591,721; 4,426,330;  
4,534,899; 5,013,556; 5,108,921; 5,213,804; 5,227,170;  
35 5,264,221; 5,356,633; 5,395,619; 5,416,016; 5,417,978;

5,462,854; 5,469,854; 5,512,295; 5,527,528; 5,534,259;  
5,543,152; 5,556,948; 5,580,575; and 5,595,756, each of  
which is herein incorporated by reference.

The antisense compounds of the invention encompass any  
5 pharmaceutically acceptable salts, esters, or salts of such  
esters, or any other compound which, upon administration to  
an animal including a human, is capable of providing  
(directly or indirectly) the biologically active metabolite  
or residue thereof. Accordingly, for example, the  
10 disclosure is also drawn to prodrugs and pharmaceutically  
acceptable salts of the compounds of the invention,  
pharmaceutically acceptable salts of such prodrugs, and  
other bioequivalents.

The term "prodrug" indicates a therapeutic agent that  
15 is prepared in an inactive form that is converted to an  
active form (i.e., drug) within the body or cells thereof  
by the action of endogenous enzymes or other chemicals  
and/or conditions. In particular, prodrug versions of the  
oligonucleotides of the invention are prepared as SATE  
20 [(S-acetyl-2-thioethyl) phosphate] derivatives according to  
the methods disclosed in WO 93/24510 to Gosselin et al.,  
published December 9, 1993 or in WO 94/26764 to Imbach et  
al.

The term "pharmaceutically acceptable salts" refers to  
25 physiologically and pharmaceutically acceptable salts of  
the compounds of the invention: i.e., salts that retain the  
desired biological activity of the parent compound and do  
not impart undesired toxicological effects thereto.

Pharmaceutically acceptable base addition salts are  
30 formed with metals or amines, such as alkali and alkaline  
earth metals or organic amines. Examples of metals used as  
cations are sodium, potassium, magnesium, calcium, and the  
like. Examples of suitable amines are  
N,N'-dibenzylethylenediamine, chlorprocaine, choline,  
35 diethanolamine, dicyclohexylamine, ethylenediamine,

N-methylglucamine, and procaine (see, for example, Berge et al., "Pharmaceutical Salts," *J. of Pharma Sci.*, 1977, 66, 1-19). The base addition salts of said acidic compounds are prepared by contacting the free acid form with a  
5 sufficient amount of the desired base to produce the salt in the conventional manner. The free acid form may be regenerated by contacting the salt form with an acid and isolating the free acid in the conventional manner. The free acid forms differ from their respective salt forms  
10 somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free acid for purposes of the present invention. As used herein, a "pharmaceutical addition  
15 salt" includes a pharmaceutically acceptable salt of an acid form of one of the components of the compositions of the invention. These include organic or inorganic acid salts of the amines. Preferred acid salts are the hydrochlorides, acetates, salicylates, nitrates and phosphates. Other suitable pharmaceutically acceptable  
20 salts are well known to those skilled in the art and include basic salts of a variety of inorganic and organic acids, such as, for example, with inorganic acids, such as for example hydrochloric acid, hydrobromic acid, sulfuric acid or phosphoric acid; with organic carboxylic, sulfonic,  
25 sulfo or phospho acids or N-substituted sulfamic acids, for example acetic acid, propionic acid, glycolic acid, succinic acid, maleic acid, hydroxymaleic acid, methylmaleic acid, fumaric acid, malic acid, tartaric acid, lactic acid, oxalic acid, gluconic acid, glucaric acid,  
30 glucuronic acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, salicylic acid, 4-aminosalicylic acid, 2-phenoxybenzoic acid, 2-acetoxybenzoic acid, embonic acid, nicotinic acid or isonicotinic acid; and with amino acids, such as the 20 alpha-amino acids involved in the synthesis  
35 of proteins in nature, for example glutamic acid or

aspartic acid, and also with phenylacetic acid,  
methanesulfonic acid, ethanesulfonic acid,  
2-hydroxyethanesulfonic acid, ethane-1,2-disulfonic acid,  
benzenesulfonic acid, 4-methylbenzenesulfonic acid,  
5 naphthalene-2-sulfonic acid, naphthalene-1,5-disulfonic  
acid, 2- or 3-phosphoglycerate, glucose-6-phosphate,  
N-cyclohexylsulfamic acid (with the formation of  
cyclamates), or with other acid organic compounds, such as  
ascorbic acid. Pharmaceutically acceptable salts of  
10 compounds may also be prepared with a pharmaceutically  
acceptable cation. Suitable pharmaceutically acceptable  
cations are well known to those skilled in the art and  
include alkaline, alkaline earth, ammonium and quaternary  
ammonium cations. Carbonates or hydrogen carbonates are  
15 also possible.

For oligonucleotides, preferred examples of  
pharmaceutically acceptable salts include but are not  
limited to (a) salts formed with cations such as sodium,  
potassium, ammonium, magnesium, calcium, polyamines such as  
20 spermine and spermidine, etc.; (b) acid addition salts  
formed with inorganic acids, for example hydrochloric acid,  
hydrobromic acid, sulfuric acid, phosphoric acid, nitric  
acid and the like; (c) salts formed with organic acids  
such as, for example, acetic acid, oxalic acid, tartaric  
25 acid, succinic acid, maleic acid, fumaric acid, gluconic  
acid, citric acid, malic acid, ascorbic acid, benzoic acid,  
tannic acid, palmitic acid, alginic acid, polyglutamic  
acid, naphthalenesulfonic acid, methanesulfonic acid,  
p-toluenesulfonic acid, naphthalenedisulfonic acid,  
30 polygalacturonic acid, and the like; and (d) salts formed  
from elemental anions such as chlorine, bromine, and  
iodine.

The antisense compounds of the present invention can  
be utilized for diagnostics, therapeutics, prophylaxis and  
35 as research reagents and kits. For therapeutics, an

animal, preferably a human, suspected of having a disease or disorder which can be treated by modulating the expression of Cellular Inhibitor of Apoptosis-1 is treated by administering antisense compounds in accordance with  
5 this invention. The compounds of the invention can be utilized in pharmaceutical compositions by adding an effective amount of an antisense compound to a suitable pharmaceutically acceptable diluent or carrier. Use of the antisense compounds and methods of the invention may also  
10 be useful prophylactically, e.g., to prevent or delay infection, inflammation or tumor formation, for example.

The antisense compounds of the invention are useful for research and diagnostics, because these compounds hybridize to nucleic acids encoding Cellular Inhibitor of  
15 Apoptosis-1, enabling sandwich and other assays to easily be constructed to exploit this fact. Hybridization of the antisense oligonucleotides of the invention with a nucleic acid encoding Cellular Inhibitor of Apoptosis-1 can be detected by means known in the art. Such means may include  
20 conjugation of an enzyme to the oligonucleotide, radiolabelling of the oligonucleotide or any other suitable detection means. Kits using such detection means for detecting the level of Cellular Inhibitor of Apoptosis-1 in a sample may also be prepared.

25 The present invention also includes pharmaceutical compositions and formulations which include the antisense compounds of the invention. The pharmaceutical compositions of the present invention may be administered in a number of ways depending upon whether local or  
30 systemic treatment is desired and upon the area to be treated. Administration may be topical (including ophthalmic and to mucous membranes including vaginal and rectal delivery), pulmonary, e.g., by inhalation or insufflation of powders or aerosols, including by  
35 nebulizer; intratracheal, intranasal, epidermal and



transdermal), oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; or intracranial, e.g., intrathecal or  
5 intraventricular, administration. Oligonucleotides with at least one 2'-O-methoxyethyl modification are believed to be particularly useful for oral administration.

Pharmaceutical compositions and formulations for topical administration may include transdermal patches,  
10 ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable. Coated condoms, gloves and the like may also be useful.

15 Compositions and formulations for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, capsules, sachets or tablets. Thickeners, flavoring agents, diluents, emulsifiers, dispersing aids or binders may be desirable.

20 Compositions and formulations for parenteral, intrathecal or intraventricular administration may include sterile aqueous solutions which may also contain buffers, diluents and other suitable additives such as, but not limited to, penetration enhancers, carrier compounds and  
25 other pharmaceutically acceptable carriers or excipients.

Pharmaceutical compositions of the present invention include, but are not limited to, solutions, emulsions, and liposome-containing formulations. These compositions may be generated from a variety of components that include, but  
30 are not limited to, preformed liquids, self-emulsifying solids and self-emulsifying semisolids.

The pharmaceutical formulations of the present invention, which may conveniently be presented in unit dosage form, may be prepared according to conventional  
35 techniques well known in the pharmaceutical industry. Such

techniques include the step of bringing into association the active ingredients with the pharmaceutical carrier(s) or excipient(s). In general the formulations are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.

The compositions of the present invention may be formulated into any of many possible dosage forms such as, but not limited to, tablets, capsules, liquid syrups, soft gels, suppositories, and enemas. The compositions of the present invention may also be formulated as suspensions in aqueous, non-aqueous or mixed media. Aqueous suspensions may further contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers.

In one embodiment of the present invention the pharmaceutical compositions may be formulated and used as foams. Pharmaceutical foams include formulations such as, but not limited to, emulsions, microemulsions, creams, jellies and liposomes. While basically similar in nature these formulations vary in the components and the consistency of the final product. The preparation of such compositions and formulations is generally known to those skilled in the pharmaceutical and formulation arts and may be applied to the formulation of the compositions of the present invention.

#### Emulsions

The compositions of the present invention may be prepared and formulated as emulsions. Emulsions are typically heterogenous systems of one liquid dispersed in another in the form of droplets usually exceeding 0.1  $\mu\text{m}$  in diameter. (Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker,

Inc., New York, N.Y., volume 1, p. 199; Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., Volume 1, p. 245; Block in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 2, p. 335; Higuchi et al., in *Remington's Pharmaceutical Sciences*, Mack Publishing Co., Easton, PA, 1985, p. 301). Emulsions are often biphasic systems comprising of two immiscible liquid phases intimately mixed and dispersed with each other. In general, emulsions may be either water-in-oil (w/o) or of the oil-in-water (o/w) variety. When an aqueous phase is finely divided into and dispersed as minute droplets into a bulk oily phase the resulting composition is called a water-in-oil (w/o) emulsion. Alternatively, when an oily phase is finely divided into and dispersed as minute droplets into a bulk aqueous phase the resulting composition is called an oil-in-water (o/w) emulsion. Emulsions may contain additional components in addition to the dispersed phases and the active drug which may be present as a solution in either the aqueous phase, oily phase or itself as a separate phase. Pharmaceutical excipients such as emulsifiers, stabilizers, dyes, and anti-oxidants may also be present in emulsions as needed. Pharmaceutical emulsions may also be multiple emulsions that are comprised of more than two phases such as, for example, in the case of oil-in-water-in-oil (o/w/o) and water-in-oil-in-water (w/o/w) emulsions. Such complex formulations often provide certain advantages that simple binary emulsions do not. Multiple emulsions in which individual oil droplets of an o/w emulsion enclose small water droplets constitute a w/o/w emulsion. Likewise a system of oil droplets enclosed in globules of water stabilized in an oily continuous provides an o/w/o

emulsion.

Emulsions are characterized by little or no thermodynamic stability. Often, the dispersed or discontinuous phase of the emulsion is well dispersed into the external or continuous phase and maintained in this form through the means of emulsifiers or the viscosity of the formulation. Either of the phases of the emulsion may be a semisolid or a solid, as is the case of emulsion-style ointment bases and creams. Other means of stabilizing emulsions entail the use of emulsifiers that may be incorporated into either phase of the emulsion. Emulsifiers may broadly be classified into four categories: synthetic surfactants, naturally occurring emulsifiers, absorption bases, and finely dispersed solids (Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199).

Synthetic surfactants, also known as surface active agents, have found wide applicability in the formulation of emulsions and have been reviewed in the literature (Rieger, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 285; Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), Marcel Dekker, Inc., New York, N.Y., 1988, volume 1, p. 199). Surfactants are typically amphiphilic and comprise a hydrophilic and a hydrophobic portion. The ratio of the hydrophilic to the hydrophobic nature of the surfactant has been termed the hydrophile/lipophile balance (HLB) and is a valuable tool in categorizing and selecting surfactants in the preparation of formulations. Surfactants may be classified into different classes based on the nature of the hydrophilic group: nonionic, anionic, cationic and amphoteric (Rieger, in *Pharmaceutical Dosage Forms*,

Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 285).

Naturally occurring emulsifiers used in emulsion formulations include lanolin, beeswax, phosphatides, lecithin and acacia. Absorption bases possess hydrophilic properties such that they can soak up water to form w/o emulsions yet retain their semisolid consistencies, such as anhydrous lanolin and hydrophilic petrolatum. Finely divided solids have also been used as good emulsifiers especially in combination with surfactants and in viscous preparations. These include polar inorganic solids, such as heavy metal hydroxides, nonswelling clays such as bentonite, attapulgite, hectorite, kaolin, montmorillonite, colloidal aluminum silicate and colloidal magnesium aluminum silicate, pigments and nonpolar solids such as carbon or glyceryl tristearate.

A large variety of non-emulsifying materials are also included in emulsion formulations and contribute to the properties of emulsions. These include fats, oils, waxes, fatty acids, fatty alcohols, fatty esters, humectants, hydrophilic colloids, preservatives and antioxidants (Block, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 335; Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199).

Hydrophilic colloids or hydrocolloids include naturally occurring gums and synthetic polymers such as polysaccharides (for example, acacia, agar, alginic acid, carrageenan, guar gum, karaya gum, and tragacanth), cellulose derivatives (for example, carboxymethyl cellulose and carboxypropyl cellulose), and synthetic polymers (for example, carbomers, cellulose ethers, and carboxyvinyl polymers). These disperse or swell in water to form colloidal solutions that stabilize emulsions by

forming strong interfacial films around the dispersed-phase droplets and by increasing the viscosity of the external phase.

Since emulsions often contain a number of ingredients  
5 such as carbohydrates, proteins, sterols and phosphatides that may readily support the growth of microbes, these formulations often incorporate preservatives. Commonly used preservatives included in emulsion formulations include methyl paraben, propyl paraben, quaternary ammonium  
10 salts, benzalkonium chloride, esters of p-hydroxybenzoic acid, and boric acid. Antioxidants are also commonly added to emulsion formulations to prevent deterioration of the formulation. Antioxidants used may be free radical scavengers such as tocopherols, alkyl gallates, butylated  
15 hydroxyanisole, butylated hydroxytoluene, or reducing agents such as ascorbic acid and sodium metabisulfite, and antioxidant synergists such as citric acid, tartaric acid, and lecithin.

The application of emulsion formulations via  
20 dermatological, oral and parenteral routes and methods for their manufacture have been reviewed in the literature (Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199). Emulsion formulations for oral  
25 delivery have been very widely used because of reasons of ease of formulation, efficacy from an absorption and bioavailability standpoint. (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245;  
30 Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199). Mineral-oil base laxatives, oil-soluble vitamins and high fat nutritive preparations are among the materials that have commonly been administered  
35 orally as o/w emulsions.

In one embodiment of the present invention, the compositions of oligonucleotides and nucleic acids are formulated as microemulsions. A microemulsion may be defined as a system of water, oil and amphiphile which is a single optically isotropic and thermodynamically stable liquid solution (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245). Typically microemulsions are systems that are prepared by first dispersing an oil in an aqueous surfactant solution and then adding a sufficient amount of a fourth component, generally an intermediate chain-length alcohol to form a transparent system. Therefore, microemulsions have also been described as thermodynamically stable, isotropically clear dispersions of two immiscible liquids that are stabilized by interfacial films of surface-active molecules (Leung and Shah, in: *Controlled Release of Drugs: Polymers and Aggregate Systems*, Rosoff, M., Ed., 1989, VCH Publishers, New York, pages 185-215). Microemulsions commonly are prepared via a combination of three to five components that include oil, water, surfactant, cosurfactant and electrolyte. Whether the microemulsion is of the water-in-oil (w/o) or an oil-in-water (o/w) type is dependent on the properties of the oil and surfactant used and on the structure and geometric packing of the polar heads and hydrocarbon tails of the surfactant molecules (Schott, in *Remington's Pharmaceutical Sciences*, Mack Publishing Co., Easton, PA, 1985, p. 271).

The phenomenological approach utilizing phase diagrams has been extensively studied and has yielded a comprehensive knowledge, to one skilled in the art, of how to formulate microemulsions (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245;

Block, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 335). Compared to conventional emulsions, microemulsions offer the advantage of

5 solubilizing water-insoluble drugs in a formulation of thermodynamically stable droplets that are formed spontaneously.

Surfactants used in the preparation of microemulsions include, but are not limited to, ionic surfactants, non-ionic surfactants, Brij 96, polyoxyethylene oleyl ethers, polyglycerol fatty acid esters, tetraglycerol monolaurate (ML310), tetraglycerol monooleate (MO310), hexaglycerol monooleate (PO310), hexaglycerol pentaoleate (PO500), decaglycerol monocaprates (MCA750), decaglycerol monooleate

15 (MO750), decaglycerol sequioleate (SO750), decaglycerol decaoleate (DAO750), alone or in combination with cosurfactants. The cosurfactant, usually a short-chain alcohol such as ethanol, 1-propanol, and 1-butanol, serves to increase the interfacial fluidity by penetrating into

20 the surfactant film and consequently creating a disordered film because of the void space generated among surfactant molecules. Microemulsions may, however, be prepared without the use of cosurfactants and alcohol-free self-emulsifying microemulsion systems are known in the art.

25 The aqueous phase may typically be, but is not limited to, water, an aqueous solution of the drug, glycerol, PEG300, PEG400, polyglycerols, propylene glycols, and derivatives of ethylene glycol. The oil phase may include, but is not limited to, materials such as Captex 300, Captex 355,

30 Capmul MCM, fatty acid esters, medium chain (C8-C12) mono, di, and tri-glycerides, polyoxyethylated glyceryl fatty acid esters, fatty alcohols, polyglycolized glycerides, saturated polyglycolized C8-C10 glycerides, vegetable oils and silicone oil.

35 Microemulsions are particularly of interest from the



standpoint of drug solubilization and the enhanced absorption of drugs. Lipid based microemulsions (both o/w and w/o) have been proposed to enhance the oral bioavailability of drugs, including peptides

- 5 (Constantinides et al., *Pharmaceutical Research*, **1994**, *11*, 1385-1390; Ritschel, *Meth. Find. Exp. Clin. Pharmacol.*, **1993**, *13*, 205). Microemulsions afford advantages of improved drug solubilization, protection of drug from enzymatic hydrolysis, possible enhancement of drug
- 10 absorption due to surfactant-induced alterations in membrane fluidity and permeability, ease of preparation, ease of oral administration over solid dosage forms, improved clinical potency, and decreased toxicity (Constantinides et al., *Pharmaceutical Research*, **1994**, *11*,
- 15 1385; Ho et al., *J. Pharm. Sci.*, **1996**, *85*, 138-143). Often microemulsions may form spontaneously when their components are brought together at ambient temperature. This may be particularly advantageous when formulating thermolabile drugs, peptides or oligonucleotides. Microemulsions have
- 20 also been effective in the transdermal delivery of active components in both cosmetic and pharmaceutical applications. It is expected that the microemulsion compositions and formulations of the present invention will facilitate the increased systemic absorption of
- 25 oligonucleotides and nucleic acids from the gastrointestinal tract, as well as improve the local cellular uptake of oligonucleotides and nucleic acids within the gastrointestinal tract, vagina, buccal cavity and other areas of administration.
- 30 Microemulsions of the present invention may also contain additional components and additives such as sorbitan monostearate (Grill 3), Labrasol, and penetration enhancers to improve the properties of the formulation and to enhance the absorption of the oligonucleotides and

nucleic acids of the present invention. Penetration enhancers used in the microemulsions of the present invention may be classified as belonging to one of five broad categories - surfactants, fatty acids, bile salts, 5 chelating agents, and non-chelating non-surfactants (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, p. 92). Each of these classes has been discussed above.

#### Liposomes

10 There are many organized surfactant structures besides microemulsions that have been studied and used for the formulation of drugs. These include monolayers, micelles, bilayers and vesicles. Vesicles, such as liposomes, have attracted great interest because of their specificity and 15 the duration of action they offer from the standpoint of drug delivery. As used in the present invention, the term "liposome" means a vesicle composed of amphiphilic lipids arranged in a spherical bilayer or bilayers.

Liposomes are unilamellar or multilamellar vesicles 20 which have a membrane formed from a lipophilic material and an aqueous interior. The aqueous portion contains the composition to be delivered. Cationic liposomes possess the advantage of being able to fuse to the cell wall. Non-cationic liposomes, although not able to fuse as 25 efficiently with the cell wall, are taken up by macrophages *in vivo*.

In order to cross intact mammalian skin, lipid vesicles must pass through a series of fine pores, each with a diameter less than 50 nm, under the influence of a 30 suitable transdermal gradient. Therefore, it is desirable to use a liposome which is highly deformable and able to pass through such fine pores.

Further advantages of liposomes include; liposomes obtained from natural phospholipids are biocompatible and 35 biodegradable; liposomes can incorporate a wide range of

water and lipid soluble drugs; liposomes can protect encapsulated drugs in their internal compartments from metabolism and degradation (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245). Important considerations in the preparation of liposome formulations are the lipid surface charge, vesicle size and the aqueous volume of the liposomes.

Liposomes are useful for the transfer and delivery of active ingredients to the site of action. Because the liposomal membrane is structurally similar to biological membranes, when liposomes are applied to a tissue, the liposomes start to merge with the cellular membranes. As the merging of the liposome and cell progresses, the liposomal contents are emptied into the cell where the active agent may act.

Liposomal formulations have been the focus of extensive investigation as the mode of delivery for many drugs. There is growing evidence that for topical administration, liposomes present several advantages over other formulations. Such advantages include reduced side-effects related to high systemic absorption of the administered drug, increased accumulation of the administered drug at the desired target, and the ability to administer a wide variety of drugs, both hydrophilic and hydrophobic, into the skin.

Several reports have detailed the ability of liposomes to deliver agents including high-molecular weight DNA into the skin. Compounds including analgesics, antibodies, hormones and high-molecular weight DNAs have been administered to the skin. The majority of applications resulted in the targeting of the upper epidermis.

Liposomes fall into two broad classes. Cationic liposomes are positively charged liposomes which interact with the negatively charged DNA molecules to form a stable

complex. The positively charged DNA/liposome complex binds to the negatively charged cell surface and is internalized in an endosome. Due to the acidic pH within the endosome, the liposomes are ruptured, releasing their contents into the cell cytoplasm (Wang et al., *Biochem. Biophys. Res. Commun.*, **1987**, 147, 980-985).

Liposomes which are pH-sensitive or negatively-charged, entrap DNA rather than complex with it. Since both the DNA and the lipid are similarly charged, repulsion rather than complex formation occurs. Nevertheless, some DNA is entrapped within the aqueous interior of these liposomes. pH-sensitive liposomes have been used to deliver DNA encoding the thymidine kinase gene to cell monolayers in culture. Expression of the exogenous gene was detected in the target cells (Zhou et al., *Journal of Controlled Release*, **1992**, 19, 269-274).

One major type of liposomal composition includes phospholipids other than naturally-derived phosphatidylcholine. Neutral liposome compositions, for example, can be formed from dimyristoyl phosphatidylcholine (DMPC) or dipalmitoyl phosphatidylcholine (DPPC). Anionic liposome compositions generally are formed from dimyristoyl phosphatidylglycerol, while anionic fusogenic liposomes are formed primarily from dioleoyl phosphatidylethanolamine (DOPE). Another type of liposomal composition is formed from phosphatidylcholine (PC) such as, for example, soybean PC, and egg PC. Another type is formed from mixtures of phospholipid and/or phosphatidylcholine and/or cholesterol.

Several studies have assessed the topical delivery of liposomal drug formulations to the skin. Application of liposomes containing interferon to guinea pig skin resulted in a reduction of skin herpes sores while delivery of interferon via other means (e.g. as a solution or as an emulsion) were ineffective (Weiner et al., *Journal of Drug*

Targeting, 1992, 2, 405-410). Further, an additional study tested the efficacy of interferon administered as part of a liposomal formulation to the administration of interferon using an aqueous system, and concluded that the liposomal  
5 formulation was superior to aqueous administration (du Plessis et al., *Antiviral Research*, 1992, 18, 259-265).

Non-ionic liposomal systems have also been examined to determine their utility in the delivery of drugs to the skin, in particular systems comprising non-ionic surfactant  
10 and cholesterol. Non-ionic liposomal formulations comprising Novasome™ I (glyceryl dilaurate/cholesterol/polyoxyethylene-10-stearyl ether) and Novasome™ II (glyceryl distearate/cholesterol/polyoxyethylene-10-stearyl ether) were used to  
15 deliver cyclosporin-A into the dermis of mouse skin. Results indicated that such non-ionic liposomal systems were effective in facilitating the deposition of cyclosporin-A into different layers of the skin (Hu et al. *S.T.P. Pharma. Sci.*, 1994, 4, 6, 466).

20 Liposomes also include "sterically stabilized" liposomes, a term which, as used herein, refers to liposomes comprising one or more specialized lipids that, when incorporated into liposomes, result in enhanced circulation lifetimes relative to liposomes lacking such  
25 specialized lipids. Examples of sterically stabilized liposomes are those in which part of the vesicle-forming lipid portion of the liposome (A) comprises one or more glycolipids, such as monosialoganglioside G<sub>M1</sub>, or (B) is derivatized with one or more hydrophilic polymers, such as  
30 a polyethylene glycol (PEG) moiety. While not wishing to be bound by any particular theory, it is thought in the art that, at least for sterically stabilized liposomes containing gangliosides, sphingomyelin, or PEG-derivatized lipids, the enhanced circulation half-life of these  
35 sterically stabilized liposomes derives from a reduced

uptake into cells of the reticuloendothelial system (RES) (Allen et al., *FEBS Letters*, **1987**, 223, 42; Wu et al., *Cancer Research*, **1993**, 53, 3765). Various liposomes

comprising one or more glycolipids are known in the art.

- 5 Papahadjopoulos et al. (*Ann. N.Y. Acad. Sci.*, **1987**, 507, 64) reported the ability of monosialoganglioside G<sub>M1</sub>, galactocerebroside sulfate and phosphatidylinositol to improve blood half-lives of liposomes. These findings were expounded upon by Gabizon et al. (*Proc. Natl. Acad. Sci.*
- 10 *U.S.A.*, **1988**, 85, 6949). U.S. Patent No. 4,837,028 and WO 88/04924, both to Allen et al., disclose liposomes comprising (1) sphingomyelin and (2) the ganglioside G<sub>M1</sub> or a galactocerebroside sulfate ester. U.S. Patent No. 5,543,152 (Webb et al.) discloses liposomes comprising
- 15 sphingomyelin. Liposomes comprising 1,2-sn-dimyristoylphosphatidylcholine are disclosed in WO 97/13499 (Lim et al.).

- Many liposomes comprising lipids derivatized with one or more hydrophilic polymers, and methods of preparation
- 20 thereof, are known in the art. Sunamoto et al. (*Bull. Chem. Soc. Jpn.*, **1980**, 53, 2778) described liposomes comprising a nonionic detergent, 2C<sub>12</sub>15G, that contains a PEG moiety. Illum et al. (*FEBS Lett.*, **1984**, 167, 79) noted that hydrophilic coating of polystyrene particles with
- 25 polymeric glycols results in significantly enhanced blood half-lives. Synthetic phospholipids modified by the attachment of carboxylic groups of polyalkylene glycols (e.g., PEG) are described by Sears (U.S. Patent Nos. 4,426,330 and 4,534,899). Klivanov et al. (*FEBS Lett.*,
- 30 **1990**, 268, 235) described experiments demonstrating that liposomes comprising phosphatidylethanolamine (PE) derivatized with PEG or PEG stearate have significant increases in blood circulation half-lives. Blume et al. (*Biochimica et Biophysica Acta*, **1990**, 1029, 91) extended

such observations to other PEG-derivatized phospholipids, e.g., DSPE-PEG, formed from the combination of distearoylphosphatidylethanolamine (DSPE) and PEG.

Liposomes having covalently bound PEG moieties on their external surface are described in European Patent No. EP 0 445 131 B1 and WO 90/04384 to Fisher. Liposome compositions containing 1-20 mole percent of PE derivatized with PEG, and methods of use thereof, are described by Woodle et al. (U.S. Patent Nos. 5,013,556 and 5,356,633) and Martin et al. (U.S. Patent No. 5,213,804 and European Patent No. EP 0 496 813 B1). Liposomes comprising a number of other lipid-polymer conjugates are disclosed in WO 91/05545 and U.S. Patent No. 5,225,212 (both to Martin et al.) and in WO 94/20073 (Zalipsky et al.) Liposomes comprising PEG-modified ceramide lipids are described in WO 96/10391 (Choi et al.). U.S. Patent Nos. 5,540,935 (Miyazaki et al.) and 5,556,948 (Tagawa et al.) describe PEG-containing liposomes that can be further derivatized with functional moieties on their surfaces.

A limited number of liposomes comprising nucleic acids are known in the art. WO 96/40062 to Thierry et al. discloses methods for encapsulating high molecular weight nucleic acids in liposomes. U.S. Patent No. 5,264,221 to Tagawa et al. discloses protein-bonded liposomes and asserts that the contents of such liposomes may include an antisense RNA. U.S. Patent No. 5,665,710 to Rahman et al. describes certain methods of encapsulating oligodeoxynucleotides in liposomes. WO 97/04787 to Love et al. discloses liposomes comprising antisense oligonucleotides targeted to the raf gene.

Transfersomes are yet another type of liposomes, and are highly deformable lipid aggregates which are attractive candidates for drug delivery vehicles. Transfersomes may be described as lipid droplets which are so highly

deformable that they are easily able to penetrate through pores which are smaller than the droplet. Transfersomes are adaptable to the environment in which they are used, e.g. they are self-optimizing (adaptive to the shape of pores in the skin), self-repairing, frequently reach their targets without fragmenting, and often self-loading. To make transfersomes it is possible to add surface edge-activators, usually surfactants, to a standard liposomal composition. Transfersomes have been used to deliver serum albumin to the skin. The transfersome-mediated delivery of serum albumin has been shown to be as effective as subcutaneous injection of a solution containing serum albumin.

Surfactants find wide application in formulations such as emulsions (including microemulsions) and liposomes. The most common way of classifying and ranking the properties of the many different types of surfactants, both natural and synthetic, is by the use of the hydrophile/lipophile balance (HLB). The nature of the hydrophilic group (also known as the "head") provides the most useful means for categorizing the different surfactants used in formulations (Rieger, in *Pharmaceutical Dosage Forms*, Marcel Dekker, Inc., New York, NY, 1988, p. 285).

If the surfactant molecule is not ionized, it is classified as a nonionic surfactant. Nonionic surfactants find wide application in pharmaceutical and cosmetic products and are usable over a wide range of pH values. In general their HLB values range from 2 to about 18 depending on their structure. Nonionic surfactants include nonionic esters such as ethylene glycol esters, propylene glycol esters, glyceryl esters, polyglyceryl esters, sorbitan esters, sucrose esters, and ethoxylated esters. Nonionic alkanolamides and ethers such as fatty alcohol ethoxylates, propoxylated alcohols, and ethoxylated/propoxylated block polymers are also included in this class. The



polyoxyethylene surfactants are the most popular members of the nonionic surfactant class.

If the surfactant molecule carries a negative charge when it is dissolved or dispersed in water, the surfactant is classified as anionic. Anionic surfactants include carboxylates such as soaps, acyl lactylates, acyl amides of amino acids, esters of sulfuric acid such as alkyl sulfates and ethoxylated alkyl sulfates, sulfonates such as alkyl benzene sulfonates, acyl isethionates, acyl taurates and sulfosuccinates, and phosphates. The most important members of the anionic surfactant class are the alkyl sulfates and the soaps.

If the surfactant molecule carries a positive charge when it is dissolved or dispersed in water, the surfactant is classified as cationic. Cationic surfactants include quaternary ammonium salts and ethoxylated amines. The quaternary ammonium salts are the most used members of this class.

If the surfactant molecule has the ability to carry either a positive or negative charge, the surfactant is classified as amphoteric. Amphoteric surfactants include acrylic acid derivatives, substituted alkylamides, N-alkylbetaines and phosphatides.

The use of surfactants in drug products, formulations and in emulsions has been reviewed (Rieger, in *Pharmaceutical Dosage Forms*, Marcel Dekker, Inc., New York, NY, 1988, p. 285).

#### Penetration Enhancers

In one embodiment, the present invention employs various penetration enhancers to effect the efficient delivery of nucleic acids, particularly oligonucleotides, to the skin of animals. Most drugs are present in solution in both ionized and nonionized forms. However, usually only lipid soluble or lipophilic drugs readily cross cell membranes. It has been discovered that even non-lipophilic

-40-

drugs may cross cell membranes if the membrane to be crossed is treated with a penetration enhancer. In addition to aiding the diffusion of non-lipophilic drugs across cell membranes, penetration enhancers also enhance the permeability of lipophilic drugs.

Penetration enhancers may be classified as belonging to one of five broad categories, i.e., surfactants, fatty acids, bile salts, chelating agents, and non-chelating non-surfactants (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, p.92). Each of the above mentioned classes of penetration enhancers are described below in greater detail.

Surfactants: In connection with the present invention, surfactants (or "surface-active agents") are chemical entities which, when dissolved in an aqueous solution, reduce the surface tension of the solution or the interfacial tension between the aqueous solution and another liquid, with the result that absorption of oligonucleotides through the mucosa is enhanced. In addition to bile salts and fatty acids, these penetration enhancers include, for example, sodium lauryl sulfate, polyoxyethylene-9-lauryl ether and polyoxyethylene-20-cetyl ether) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, p.92); and perfluorochemical emulsions, such as FC-43. Takahashi et al., *J. Pharm. Pharmacol.*, 1988, 40, 252).

Fatty acids: Various fatty acids and their derivatives which act as penetration enhancers include, for example, oleic acid, lauric acid, capric acid (n-decanoic acid), myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, tricaprate, monoolein (1-monooleoyl-rac-glycerol), dilaurin, caprylic acid, arachidonic acid, glycerol 1-monocaprate, 1-dodecylazacycloheptan-2-one, acylcarnitines, acylcholines,

C<sub>1-10</sub> alkyl esters thereof (e.g., methyl, isopropyl and t-butyl), and mono- and di-glycerides thereof (i.e., oleate, laurate, caprate, myristate, palmitate, stearate, linoleate, etc.) (Lee et al., *Critical Reviews in*

- 5 *Therapeutic Drug Carrier Systems*, 1991, p.92; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1990, 7, 1-33; El Hariri et al., *J. Pharm. Pharmacol.*, 1992, 44, 651-654).

Bile salts: The physiological role of bile includes  
10 the facilitation of dispersion and absorption of lipids and fat-soluble vitamins (Brunton, Chapter 38 in: Goodman & Gilman's *The Pharmacological Basis of Therapeutics*, 9th Ed., Hardman et al. Eds., McGraw-Hill, New York, 1996, pp. 934-935). Various natural bile salts, and their synthetic  
15 derivatives, act as penetration enhancers. Thus the term "bile salts" includes any of the naturally occurring components of bile as well as any of their synthetic derivatives. The bile salts of the invention include, for example, cholic acid (or its pharmaceutically acceptable  
20 sodium salt, sodium cholate), dehydrocholic acid (sodium dehydrocholate), deoxycholic acid (sodium deoxycholate), glucolic acid (sodium glucolate), glycholic acid (sodium glycocholate), glycodeoxycholic acid (sodium glycodeoxycholate), taurocholic acid (sodium taurocholate),  
25 taurodeoxycholic acid (sodium taurodeoxycholate), chenodeoxycholic acid (sodium chenodeoxycholate), ursodeoxycholic acid (UDCA), sodium tauro-24,25-dihydrofusidate (STDHF), sodium glycodihydrofusidate and polyoxyethylene-9-lauryl ether (POE) (Lee et al., *Critical*  
30 *Reviews in Therapeutic Drug Carrier Systems*, 1991, page 92; Swinyard, Chapter 39 In: *Remington's Pharmaceutical Sciences*, 18th Ed., Gennaro, ed., Mack Publishing Co., Easton, PA, 1990, pages 782-783; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1990, 7, 1-33;

Yamamoto et al., *J. Pharm. Exp. Ther.*, **1992**, 263, 25;

Yamashita et al., *J. Pharm. Sci.*, **1990**, 79, 579-583).

Chelating Agents: Chelating agents, as used in connection with the present invention, can be defined as compounds that remove metallic ions from solution by forming complexes therewith, with the result that absorption of oligonucleotides through the mucosa is enhanced. With regards to their use as penetration enhancers in the present invention, chelating agents have the added advantage of also serving as DNase inhibitors, as most characterized DNA nucleases require a divalent metal ion for catalysis and are thus inhibited by chelating agents (Jarrett, *J. Chromatogr.*, **1993**, 618, 315-339). Chelating agents of the invention include but are not limited to disodium ethylenediaminetetraacetate (EDTA), citric acid, salicylates (e.g., sodium salicylate, 5-methoxysalicylate and homovanilate), *N*-acyl derivatives of collagen, laureth-9 and *N*-amino acyl derivatives of beta-diketones (enamines) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, **1991**, page 92; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, **1990**, 7, 1-33; Buur et al., *J. Control Rel.*, **1990**, 14, 43-51).

Non-chelating non-surfactants: As used herein, non-chelating non-surfactant penetration enhancing compounds can be defined as compounds that demonstrate insignificant activity as chelating agents or as surfactants but that nonetheless enhance absorption of oligonucleotides through the alimentary mucosa (Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, **1990**, 7, 1-33). This class of penetration enhancers include, for example, unsaturated cyclic ureas, 1-alkyl- and 1-alkenylazacycloalkanone derivatives (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, **1991**, page 92); and non-steroidal anti-inflammatory agents such as diclofenac

sodium, indomethacin and phenylbutazone (Yamashita et al., *J. Pharm. Pharmacol.*, **1987**, 39, 621-626).

Agents that enhance uptake of oligonucleotides at the cellular level may also be added to the pharmaceutical and other compositions of the present invention. For example, cationic lipids, such as lipofectin (Junichi et al, U.S. Patent No. 5,705,188), cationic glycerol derivatives, and polycationic molecules, such as polylysine (Lollo et al., PCT Application WO 97/30731), are also known to enhance the cellular uptake of oligonucleotides.

Other agents may be utilized to enhance the penetration of the administered nucleic acids, including glycols such as ethylene glycol and propylene glycol, pyrrols such as 2-pyrrol, azones, and terpenes such as limonene and menthone.

#### Carriers

Certain compositions of the present invention also incorporate carrier compounds in the formulation. As used herein, "carrier compound" or "carrier" can refer to a nucleic acid, or analog thereof, which is inert (i.e., does not possess biological activity per se) but is recognized as a nucleic acid by *in vivo* processes that reduce the bioavailability of a nucleic acid having biological activity by, for example, degrading the biologically active nucleic acid or promoting its removal from circulation. The coadministration of a nucleic acid and a carrier compound, typically with an excess of the latter substance, can result in a substantial reduction of the amount of nucleic acid recovered in the liver, kidney or other extracirculatory reservoirs, presumably due to competition between the carrier compound and the nucleic acid for a common receptor. For example, the recovery of a partially phosphorothioate oligonucleotide in hepatic tissue can be reduced when it is coadministered with polyinosinic acid, dextran sulfate, polycytidic acid or 4-acetamido-

4'isothiocyano-stilbene-2,2'-disulfonic acid (Miyao et al.,  
*Antisense Res. Dev.*, **1995**, 5, 115-121; Takakura et al.,  
*Antisense & Nucl. Acid Drug Dev.*, **1996**, 6, 177-183).

#### Excipients

5 In contrast to a carrier compound, a "pharmaceutical  
carrier" or "excipient" is a pharmaceutically acceptable  
solvent, suspending agent or any other pharmacologically  
inert vehicle for delivering one or more nucleic acids to  
an animal. The excipient may be liquid or solid and is  
10 selected, with the planned manner of administration in  
mind, so as to provide for the desired bulk, consistency,  
etc., when combined with a nucleic acid and the other  
components of a given pharmaceutical composition. Typical  
pharmaceutical carriers include, but are not limited to,  
15 binding agents (e.g., pregelatinized maize starch,  
polyvinylpyrrolidone or hydroxypropyl methylcellulose,  
etc.); fillers (e.g., lactose and other sugars,  
microcrystalline cellulose, pectin, gelatin, calcium  
sulfate, ethyl cellulose, polyacrylates or calcium hydrogen  
20 phosphate, etc.); lubricants (e.g., magnesium stearate,  
talc, silica, colloidal silicon dioxide, stearic acid,  
metallic stearates, hydrogenated vegetable oils, corn  
starch, polyethylene glycols, sodium benzoate, sodium  
acetate, etc.); disintegrants (e.g., starch, sodium starch  
25 glycolate, etc.); and wetting agents (e.g., sodium lauryl  
sulphate, etc.).

Pharmaceutically acceptable organic or inorganic  
excipient suitable for non-parenteral administration which  
do not deleteriously react with nucleic acids can also be  
30 used to formulate the compositions of the present  
invention. Suitable pharmaceutically acceptable carriers  
include, but are not limited to, water, salt solutions,  
alcohols, polyethylene glycols, gelatin, lactose, amylose,  
magnesium stearate, talc, silicic acid, viscous paraffin,

hydroxymethylcellulose, polyvinylpyrrolidone and the like.

Formulations for topical administration of nucleic acids may include sterile and non-sterile aqueous solutions, non-aqueous solutions in common solvents such as  
5 alcohols, or solutions of the nucleic acids in liquid or solid oil bases. The solutions may also contain buffers, diluents and other suitable additives. Pharmaceutically acceptable organic or inorganic excipients suitable for non-parenteral administration which do not deleteriously  
10 react with nucleic acids can be used.

Suitable pharmaceutically acceptable excipients include, but are not limited to, water, salt solutions, alcohol, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin,  
15 hydroxymethylcellulose, polyvinylpyrrolidone and the like.

#### Other Components

The compositions of the present invention may additionally contain other adjunct components conventionally found in pharmaceutical compositions, at  
20 their art-established usage levels. Thus, for example, the compositions may contain additional, compatible, pharmaceutically-active materials such as, for example, antipruritics, astringents, local anesthetics or anti-inflammatory agents, or may contain additional  
25 materials useful in physically formulating various dosage forms of the compositions of the present invention, such as dyes, flavoring agents, preservatives, antioxidants, opacifiers, thickening agents and stabilizers. However, such materials, when added, should not unduly interfere  
30 with the biological activities of the components of the compositions of the present invention. The formulations can be sterilized and, if desired, mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic  
35 pressure, buffers, colorings, flavorings and/or aromatic

substances and the like which do not deleteriously interact with the nucleic acid(s) of the formulation.

Aqueous suspensions may contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers.

Certain embodiments of the invention provide pharmaceutical compositions containing (a) one or more antisense compounds and (b) one or more other chemotherapeutic agents which function by a non-antisense mechanism. Examples of such chemotherapeutic agents include, but are not limited to, anticancer drugs such as daunorubicin, dactinomycin, doxorubicin, bleomycin, mitomycin, nitrogen mustard, chlorambucil, melphalan, cyclophosphamide, 6-mercaptopurine, 6-thioguanine, cytarabine (CA), 5-fluorouracil (5-FU), floxuridine (5-FUdR), methotrexate (MTX), colchicine, vincristine, vinblastine, etoposide, teniposide, cisplatin and diethylstilbestrol (DES). See, generally, *The Merck Manual of Diagnosis and Therapy*, 15th Ed., Berkow et al., eds., 1987, Rahway, N.J., pages 1206-1228). Anti-inflammatory drugs, including but not limited to nonsteroidal anti-inflammatory drugs and corticosteroids, and antiviral drugs, including but not limited to ribivirin, vidarabine, acyclovir and ganciclovir, may also be combined in compositions of the invention. See, generally, *The Merck Manual of Diagnosis and Therapy*, 15th Ed., Berkow et al., eds., 1987, Rahway, N.J., pages 2499-2506 and 46-49, respectively). Other non-antisense chemotherapeutic agents are also within the scope of this invention. Two or more combined compounds may be used together or sequentially.

In another related embodiment, compositions of the invention may contain one or more antisense compounds, particularly oligonucleotides, targeted to a first nucleic acid and one or more additional antisense compounds



targeted to a second nucleic acid target. Numerous examples of antisense compounds are known in the art. Two or more combined compounds may be used together or sequentially.

The formulation of therapeutic compositions and their subsequent administration is believed to be within the skill of those in the art. Dosing is dependent on severity and responsiveness of the disease state to be treated, with the course of treatment lasting from several days to several months, or until a cure is effected or a diminution of the disease state is achieved. Optimal dosing schedules can be calculated from measurements of drug accumulation in the body of the patient. Persons of ordinary skill can easily determine optimum dosages, dosing methodologies and repetition rates. Optimum dosages may vary depending on the relative potency of individual oligonucleotides, and can generally be estimated based on  $EC_{50}$ s found to be effective in in vitro and in vivo animal models. In general, dosage is from 0.01 ug to 100 g per kg of body weight, and may be given once or more daily, weekly, monthly or yearly, or even once every 2 to 20 years. Persons of ordinary skill in the art can easily estimate repetition rates for dosing based on measured residence times and concentrations of the drug in bodily fluids or tissues. Following successful treatment, it may be desirable to have the patient undergo maintenance therapy to prevent the recurrence of the disease state, wherein the oligonucleotide is administered in maintenance doses, ranging from 0.01 ug to 100 g per kg of body weight, once or more daily, to once every 20 years.

While the present invention has been described with specificity in accordance with certain of its preferred embodiments, the following examples serve only to illustrate the invention and are not intended to limit the same.

## EXAMPLES

**Example 1****Nucleoside Phosphoramidites for Oligonucleotide Synthesis  
Deoxy and 2'-alkoxy amidites**

5           2'-Deoxy and 2'-methoxy beta-cyanoethyldiisopropyl  
phosphoramidites were purchased from commercial sources  
(e.g. Chemgenes, Needham MA or Glen Research, Inc. Sterling  
VA). Other 2'-O-alkoxy substituted nucleoside amidites are  
prepared as described in U.S. Patent 5,506,351, herein  
10 incorporated by reference. For oligonucleotides  
synthesized using 2'-alkoxy amidites, the standard cycle  
for unmodified oligonucleotides was utilized, except the  
wait step after pulse delivery of tetrazole and base was  
increased to 360 seconds.

15           Oligonucleotides containing 5-methyl-2'-deoxycytidine  
(5-Me-C) nucleotides were synthesized according to  
published methods [Sanghvi, et. al., *Nucleic Acids  
Research*, **1993**, 21, 3197-3203] using commercially available  
phosphoramidites (Glen Research, Sterling VA or ChemGenes,  
20 Needham MA).

**2'-Fluoro amidites****2'-Fluorodeoxyadenosine amidites**

2'-fluoro oligonucleotides were synthesized as  
described previously [Kawasaki, et. al., *J. Med. Chem.*,  
25 **1993**, 36, 831-841] and United States patent 5,670,633,  
herein incorporated by reference. Briefly, the protected  
nucleoside N6-benzoyl-2'-deoxy-2'-fluoroadenosine was  
synthesized utilizing commercially available 9-beta-D-  
arabinofuranosyladenine as starting material and by  
30 modifying literature procedures whereby the 2'-alpha-fluoro  
atom is introduced by a  $S_N2$ -displacement of a 2'-beta-trityl  
group. Thus N6-benzoyl-9-beta-D-arabinofuranosyladenine  
was selectively protected in moderate yield as the 3',5'-  
ditetrahydropyranyl (THP) intermediate. Deprotection of

the THP and N6-benzoyl groups was accomplished using standard methodologies and standard methods were used to obtain the 5'-dimethoxytrityl-(DMT) and 5'-DMT-3'-phosphoramidite intermediates.

5           **2'-Fluorodeoxyguanosine**

The synthesis of 2'-deoxy-2'-fluoroguanosine was accomplished using tetraisopropylidisiloxanyl (TPDS) protected 9-beta-D-arabinofuranosylguanine as starting material, and conversion to the intermediate diisobutyryl-arabinofuranosylguanosine. Deprotection of the TPDS group was followed by protection of the hydroxyl group with THP to give diisobutyryl di-THP protected arabinofuranosylguanine. Selective O-deacylation and triflation was followed by treatment of the crude product with fluoride, then deprotection of the THP groups. Standard methodologies were used to obtain the 5'-DMT- and 5'-DMT-3'-phosphoramidites.

**2'-Fluorouridine**

Synthesis of 2'-deoxy-2'-fluorouridine was accomplished by the modification of a literature procedure in which 2,2'-anhydro-1-beta-D-arabinofuranosyluracil was treated with 70% hydrogen fluoride-pyridine. Standard procedures were used to obtain the 5'-DMT and 5'-DMT-3'phosphoramidites.

25           **2'-Fluorodeoxycytidine**

2'-deoxy-2'-fluorocytidine was synthesized via amination of 2'-deoxy-2'-fluorouridine, followed by selective protection to give N4-benzoyl-2'-deoxy-2'-fluorocytidine. Standard procedures were used to obtain the 5'-DMT and 5'-DMT-3'phosphoramidites.

**2'-O-(2-Methoxyethyl) modified amidites**

2'-O-Methoxyethyl-substituted nucleoside amidites are prepared as follows, or alternatively, as per the methods of Martin, P., *Helvetica Chimica Acta*, 1995, 78, 486-504.

-50-

**2,2'-Anhydro[1-(beta-D-arabinofuranosyl)-5-methyluridine]**

5-Methyluridine (ribosylthymine, commercially available through Yamasa, Choshi, Japan) (72.0 g, 0.279 M),  
5 diphenylcarbonate (90.0 g, 0.420 M) and sodium bicarbonate (2.0 g, 0.024 M) were added to DMF (300 mL). The mixture was heated to reflux, with stirring, allowing the evolved carbon dioxide gas to be released in a controlled manner. After 1 hour, the slightly darkened solution was  
10 concentrated under reduced pressure. The resulting syrup was poured into diethylether (2.5 L), with stirring. The product formed a gum. The ether was decanted and the residue was dissolved in a minimum amount of methanol (ca. 400 mL). The solution was poured into fresh ether (2.5 L)  
15 to yield a stiff gum. The ether was decanted and the gum was dried in a vacuum oven (60°C at 1 mm Hg for 24 h) to give a solid that was crushed to a light tan powder (57 g, 85% crude yield). The NMR spectrum was consistent with the structure, contaminated with phenol as its sodium salt (ca.  
20 5%). The material was used as is for further reactions (or it can be purified further by column chromatography using a gradient of methanol in ethyl acetate (10-25%) to give a white solid, mp 222-4°C).

**2'-O-Methoxyethyl-5-methyluridine**

25 2,2'-Anhydro-5-methyluridine (195 g, 0.81 M), tris(2-methoxyethyl)borate (231 g, 0.98 M) and 2-methoxyethanol (1.2 L) were added to a 2 L stainless steel pressure vessel and placed in a pre-heated oil bath at 160°C. After heating for 48 hours at 155-160°C, the vessel was opened and the  
30 solution evaporated to dryness and triturated with MeOH (200 mL). The residue was suspended in hot acetone (1 L). The insoluble salts were filtered, washed with acetone (150 mL) and the filtrate evaporated. The residue (280 g) was dissolved in CH<sub>3</sub>CN (600 mL) and evaporated. A silica gel  
35 column (3 kg) was packed in CH<sub>2</sub>Cl<sub>2</sub>/acetone/MeOH (20:5:3)

-51-

containing 0.5% Et<sub>3</sub>NH. The residue was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (250 mL) and adsorbed onto silica (150 g) prior to loading onto the column. The product was eluted with the packing solvent to give 160 g (63%) of product. Additional  
5 material was obtained by reworking impure fractions.

**2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine**

2'-O-Methoxyethyl-5-methyluridine (160 g, 0.506 M) was co-evaporated with pyridine (250 mL) and the dried residue dissolved in pyridine (1.3 L). A first aliquot of  
10 dimethoxytrityl chloride (94.3 g, 0.278 M) was added and the mixture stirred at room temperature for one hour. A second aliquot of dimethoxytrityl chloride (94.3 g, 0.278 M) was added and the reaction stirred for an additional one hour. Methanol (170 mL) was then added to stop the  
15 reaction. HPLC showed the presence of approximately 70% product. The solvent was evaporated and triturated with CH<sub>3</sub>CN (200 mL). The residue was dissolved in CHCl<sub>3</sub> (1.5 L) and extracted with 2x500 mL of saturated NaHCO<sub>3</sub> and 2x500 mL of saturated NaCl. The organic phase was dried over Na<sub>2</sub>SO<sub>4</sub>,  
20 filtered and evaporated. 275 g of residue was obtained. The residue was purified on a 3.5 kg silica gel column, packed and eluted with EtOAc/hexane/acetone (5:5:1) containing 0.5% Et<sub>3</sub>NH. The pure fractions were evaporated to give 164 g of product. Approximately 20 g additional  
25 was obtained from the impure fractions to give a total yield of 183 g (57%).

**3'-O-Acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine**

2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine  
30 (106 g, 0.167 M), DMF/pyridine (750 mL of a 3:1 mixture prepared from 562 mL of DMF and 188 mL of pyridine) and acetic anhydride (24.38 mL, 0.258 M) were combined and stirred at room temperature for 24 hours. The reaction was monitored by TLC by first quenching the TLC sample with the  
35 addition of MeOH. Upon completion of the reaction, as

-52-

judged by TLC, MeOH (50 mL) was added and the mixture evaporated at 35°C. The residue was dissolved in CHCl<sub>3</sub> (800 mL) and extracted with 2x200 mL of saturated sodium bicarbonate and 2x200 mL of saturated NaCl. The water layers were back extracted with 200 mL of CHCl<sub>3</sub>. The combined organics were dried with sodium sulfate and evaporated to give 122 g of residue (approx. 90% product). The residue was purified on a 3.5 kg silica gel column and eluted using EtOAc/hexane(4:1). Pure product fractions were evaporated to yield 96 g (84%). An additional 1.5 g was recovered from later fractions.

**3'-O-Acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyl-4-triazoleuridine**

A first solution was prepared by dissolving 3'-O-acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine (96 g, 0.144 M) in CH<sub>3</sub>CN (700 mL) and set aside. Triethylamine (189 mL, 1.44 M) was added to a solution of triazole (90 g, 1.3 M) in CH<sub>3</sub>CN (1 L), cooled to -5°C and stirred for 0.5 h using an overhead stirrer. POCl<sub>3</sub> was added dropwise, over a 30 minute period, to the stirred solution maintained at 0-10°C, and the resulting mixture stirred for an additional 2 hours. The first solution was added dropwise, over a 45 minute period, to the latter solution. The resulting reaction mixture was stored overnight in a cold room. Salts were filtered from the reaction mixture and the solution was evaporated. The residue was dissolved in EtOAc (1 L) and the insoluble solids were removed by filtration. The filtrate was washed with 1x300 mL of NaHCO<sub>3</sub> and 2x300 mL of saturated NaCl, dried over sodium sulfate and evaporated. The residue was triturated with EtOAc to give the title compound.

**2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine**

A solution of 3'-O-acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyl-4-triazoleuridine (103 g, 0.141 M)

-53-

in dioxane (500 mL) and  $\text{NH}_4\text{OH}$  (30 mL) was stirred at room temperature for 2 hours. The dioxane solution was evaporated and the residue azeotroped with MeOH (2x200 mL). The residue was dissolved in MeOH (300 mL) and transferred to a 2 liter stainless steel pressure vessel. MeOH (400 mL) saturated with  $\text{NH}_3$  gas was added and the vessel heated to  $100^\circ\text{C}$  for 2 hours (TLC showed complete conversion). The vessel contents were evaporated to dryness and the residue was dissolved in EtOAc (500 mL) and washed once with saturated NaCl (200 mL). The organics were dried over sodium sulfate and the solvent was evaporated to give 85 g (95%) of the title compound.

**N4-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine**

2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine (85 g, 0.134 M) was dissolved in DMF (800 mL) and benzoic anhydride (37.2 g, 0.165 M) was added with stirring. After stirring for 3 hours, TLC showed the reaction to be approximately 95% complete. The solvent was evaporated and the residue azeotroped with MeOH (200 mL). The residue was dissolved in  $\text{CHCl}_3$  (700 mL) and extracted with saturated  $\text{NaHCO}_3$  (2x300 mL) and saturated NaCl (2x300 mL), dried over  $\text{MgSO}_4$  and evaporated to give a residue (96 g). The residue was chromatographed on a 1.5 kg silica column using EtOAc/hexane (1:1) containing 0.5%  $\text{Et}_3\text{NH}$  as the eluting solvent. The pure product fractions were evaporated to give 90 g (90%) of the title compound.

**N4-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine-3'-amidite**

N4-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine (74 g, 0.10 M) was dissolved in  $\text{CH}_2\text{Cl}_2$  (1 L). Tetrazole diisopropylamine (7.1 g) and 2-cyanoethoxy-tetra-(isopropyl)phosphite (40.5 mL, 0.123 M) were added with stirring, under a nitrogen atmosphere. The resulting mixture was stirred for 20 hours at room temperature (TLC

-54-

showed the reaction to be 95% complete). The reaction mixture was extracted with saturated  $\text{NaHCO}_3$  (1x300 mL) and saturated  $\text{NaCl}$  (3x300 mL). The aqueous washes were back-extracted with  $\text{CH}_2\text{Cl}_2$  (300 mL), and the extracts were  
5 combined, dried over  $\text{MgSO}_4$  and concentrated. The residue obtained was chromatographed on a 1.5 kg silica column using  $\text{EtOAc}$ /hexane (3:1) as the eluting solvent. The pure fractions were combined to give 90.6 g (87%) of the title compound.

10 **2'-O-(Aminooxyethyl) nucleoside amidites and 2'-O-(dimethylaminooxyethyl) nucleoside amidites**

**2'-(Dimethylaminooxyethoxy) nucleoside amidites**

2'-(Dimethylaminooxyethoxy) nucleoside amidites [also known in the art as 2'-O-(dimethylaminooxyethyl) nucleoside  
15 amidites] are prepared as described in the following paragraphs. Adenosine, cytidine and guanosine nucleoside amidites are prepared similarly to the thymidine (5-methyluridine) except the exocyclic amines are protected with a benzoyl moiety in the case of adenosine and cytidine  
20 and with isobutyryl in the case of guanosine.

**5'-O-tert-Butyldiphenylsilyl-O<sup>2</sup>-2'-anhydro-5-methyluridine**

O<sup>2</sup>-2'-anhydro-5-methyluridine (Pro. Bio. Sint., Varese, Italy, 100.0g, 0.416 mmol); dimethylaminopyridine (0.66g,  
25 0.013eq, 0.0054mmol) were dissolved in dry pyridine (500 ml) at ambient temperature under an argon atmosphere and with mechanical stirring. tert-Butyldiphenylchlorosilane (125.8g, 119.0mL, 1.1eq, 0.458mmol) was added in one portion. The reaction was stirred for 16 h at ambient  
30 temperature. TLC ( $R_f$  0.22, ethyl acetate) indicated a complete reaction. The solution was concentrated under reduced pressure to a thick oil. This was partitioned between dichloromethane (1 L) and saturated sodium bicarbonate (2x1 L) and brine (1 L). The organic layer was



-55-

dried over sodium sulfate and concentrated under reduced pressure to a thick oil. The oil was dissolved in a 1:1 mixture of ethyl acetate and ethyl ether (600mL) and the solution was cooled to

5 -10°C. The resulting crystalline product was collected by filtration, washed with ethyl ether (3x200 mL) and dried (40°C, 1mm Hg, 24 h) to 149g (74.8%) of white solid. TLC and NMR were consistent with pure product.

10 **5'-O-tert-Butyldiphenylsilyl-2'-O-(2-hydroxyethyl)-5-methyluridine**

In a 2 L stainless steel, unstirred pressure reactor was added borane in tetrahydrofuran (1.0 M, 2.0 eq, 622 mL). In the fume hood and with manual stirring, ethylene glycol (350 mL, excess) was added cautiously at first until  
15 the evolution of hydrogen gas subsided. 5'-O-tert-Butyldiphenylsilyl-O<sup>2</sup>-2'-anhydro-5-methyluridine (149 g, 0.311 mol) and sodium bicarbonate (0.074 g, 0.003 eq) were added with manual stirring. The reactor was sealed and heated in an oil bath until an internal temperature of 160  
20 °C was reached and then maintained for 16 h (pressure < 100 psig). The reaction vessel was cooled to ambient and opened. TLC (Rf 0.67 for desired product and Rf 0.82 for ara-T side product, ethyl acetate) indicated about 70% conversion to the product. In order to avoid additional  
25 side product formation, the reaction was stopped, concentrated under reduced pressure (10 to 1mm Hg) in a warm water bath (40-100°C) with the more extreme conditions used to remove the ethylene glycol. [Alternatively, once the low boiling solvent is gone, the remaining solution can  
30 be partitioned between ethyl acetate and water. The product will be in the organic phase.] The residue was purified by column chromatography (2kg silica gel, ethyl acetate-hexanes gradient 1:1 to 4:1). The appropriate fractions were combined, stripped and dried to product as a  
35 white crisp foam (84g, 50%), contaminated starting material

(17.4g) and pure reusable starting material 20g. The yield based on starting material less pure recovered starting material was 58%. TLC and NMR were consistent with 99% pure product.

5        **2'-O-([2-phthalimidoxy)ethyl]-5'-t-butyldiphenylsilyl-5-methyluridine**

5'-O-tert-Butyldiphenylsilyl-2'-O-(2-hydroxyethyl)-5-methyluridine (20g, 36.98mmol) was mixed with triphenylphosphine (11.63g, 44.36mmol) and N-  
10 hydroxyphthalimide (7.24g, 44.36mmol). It was then dried over P<sub>2</sub>O<sub>5</sub> under high vacuum for two days at 40°C. The reaction mixture was flushed with argon and dry THF (369.8mL, Aldrich, sure seal bottle) was added to get a clear solution. Diethyl-azodicarboxylate (6.98mL,  
15 44.36mmol) was added dropwise to the reaction mixture. The rate of addition is maintained such that resulting deep red coloration is just discharged before adding the next drop. After the addition was complete, the reaction was stirred for 4 hrs. By that time TLC showed the completion of the  
20 reaction (ethylacetate:hexane, 60:40). The solvent was evaporated in vacuum. Residue obtained was placed on a flash column and eluted with ethyl acetate:hexane (60:40), to get 2'-O-([2-phthalimidoxy)ethyl]-5'-t-butyldiphenylsilyl-5-methyluridine as white foam (21.819 g,  
25 86%).

**5'-O-tert-butyldiphenylsilyl-2'-O-[(2-formadoximinooxy)ethyl]-5-methyluridine**

2'-O-([2-phthalimidoxy)ethyl]-5'-t-butyldiphenylsilyl-5-methyluridine (3.1g, 4.5mmol) was dissolved in dry CH<sub>2</sub>Cl<sub>2</sub>  
30 (4.5mL) and methylhydrazine (300mL, 4.64mmol) was added dropwise at -10°C to 0°C. After 1 h the mixture was filtered, the filtrate was washed with ice cold CH<sub>2</sub>Cl<sub>2</sub> and the combined organic phase was washed with water, brine and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. The solution was concentrated

to get 2'-O-(aminooxyethyl) thymidine, which was then dissolved in MeOH (67.5mL). To this formaldehyde (20% aqueous solution, w/w, 1.1 eq.) was added and the resulting mixture was stirred for 1 h. Solvent was removed under

- 5 vacuum; residue chromatographed to get 5'-O-tert-butyl-diphenylsilyl-2'-O-[(2-formadoximinooxy) ethyl]-5-methyluridine as white foam (1.95 g, 78%).

**5'-O-tert-Butyl-diphenylsilyl-2'-O-[N,N-dimethylaminooxyethyl]-5-methyluridine**

- 10 5'-O-tert-butyl-diphenylsilyl-2'-O-[(2-formadoximinooxy)ethyl]-5-methyluridine (1.77g, 3.12mmol) was dissolved in a solution of 1M pyridinium p-toluenesulfonate (PPTS) in dry MeOH (30.6mL). Sodium cyanoborohydride (0.39g, 6.13mmol) was added to this
- 15 solution at 10°C under inert atmosphere. The reaction mixture was stirred for 10 minutes at 10°C. After that the reaction vessel was removed from the ice bath and stirred at room temperature for 2 h, the reaction monitored by TLC (5% MeOH in CH<sub>2</sub>Cl<sub>2</sub>). Aqueous NaHCO<sub>3</sub> solution (5%, 10mL) was
- 20 added and extracted with ethyl acetate (2x20mL). Ethyl acetate phase was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, evaporated to dryness. Residue was dissolved in a solution of 1M PPTS in MeOH (30.6mL). Formaldehyde (20% w/w, 30mL, 3.37mmol) was added and the reaction mixture was stirred at room
- 25 temperature for 10 minutes. Reaction mixture cooled to 10°C in an ice bath, sodium cyanoborohydride (0.39g, 6.13mmol) was added and reaction mixture stirred at 10°C for 10 minutes. After 10 minutes, the reaction mixture was removed from the ice bath and stirred at room temperature
- 30 for 2 hrs. To the reaction mixture 5% NaHCO<sub>3</sub> (25mL) solution was added and extracted with ethyl acetate (2x25mL). Ethyl acetate layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and evaporated to dryness. The residue obtained was purified by flash column chromatography and eluted with 5%

MeOH in  $\text{CH}_2\text{Cl}_2$ , to get 5'-O-tert-butyldiphenylsilyl-2'-O-[N,N-dimethylaminoxyethyl]-5-methyluridine as a white foam (14.6g, 80%).

**2'-O-(dimethylaminoxyethyl)-5-methyluridine**

5        Triethylamine trihydrofluoride (3.91mL, 24.0mmol) was dissolved in dry THF and triethylamine (1.67mL, 12mmol, dry, kept over KOH). This mixture of triethylamine-2HF was then added to 5'-O-tert-butyldiphenylsilyl-2'-O-[N,N-dimethylaminoxyethyl]-5-methyluridine (1.40g, 2.4mmol) and  
10       stirred at room temperature for 24 hrs. Reaction was monitored by TLC (5% MeOH in  $\text{CH}_2\text{Cl}_2$ ). Solvent was removed under vacuum and the residue placed on a flash column and eluted with 10% MeOH in  $\text{CH}_2\text{Cl}_2$  to get 2'-O-(dimethylaminoxyethyl)-5-methyluridine (766mg, 92.5%).

15       **5'-O-DMT-2'-O-(dimethylaminoxyethyl)-5-methyluridine**

2'-O-(dimethylaminoxyethyl)-5-methyluridine (750mg, 2.17mmol) was dried over  $\text{P}_2\text{O}_5$  under high vacuum overnight at 40°C. It was then co-evaporated with anhydrous pyridine (20mL). The residue obtained was dissolved in pyridine  
20       (11mL) under argon atmosphere. 4-dimethylaminopyridine (26.5mg, 2.60mmol), 4,4'-dimethoxytrityl chloride (880mg, 2.60mmol) was added to the mixture and the reaction mixture was stirred at room temperature until all of the starting material disappeared. Pyridine was removed under vacuum  
25       and the residue chromatographed and eluted with 10% MeOH in  $\text{CH}_2\text{Cl}_2$  (containing a few drops of pyridine) to get 5'-O-DMT-2'-O-(dimethylamino-oxyethyl)-5-methyluridine (1.13g, 80%).

**5'-O-DMT-2'-O-(2-N,N-dimethylaminoxyethyl)-5-**

**methyluridine-3'-[(2-cyanoethyl)-N,N-**

30       **diisopropylphosphoramidite]**

5'-O-DMT-2'-O-(dimethylaminoxyethyl)-5-methyluridine (1.08g, 1.67mmol) was co-evaporated with toluene (20mL). To the residue N,N-diisopropylamine tetrazonide (0.29g, 1.67mmol) was added and dried over  $\text{P}_2\text{O}_5$  under high vacuum

overnight at 40°C. Then the reaction mixture was dissolved in anhydrous acetonitrile (8.4mL) and 2-cyanoethyl-N,N,N',N'-tetraisopropylphosphoramidite (2.12mL, 6.08mmol) was added. The reaction mixture was stirred at ambient temperature for 4 hrs under inert atmosphere. The progress of the reaction was monitored by TLC (hexane:ethyl acetate 1:1). The solvent was evaporated, then the residue was dissolved in ethyl acetate (70mL) and washed with 5% aqueous NaHCO<sub>3</sub> (40mL). Ethyl acetate layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated. Residue obtained was chromatographed (ethyl acetate as eluent) to get 5'-O-DMT-2'-O-(2-N,N-dimethylaminoxyethyl)-5-methyluridine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite] as a foam (1.04g, 74.9%).

15        **2'-(Aminooxyethoxy) nucleoside amidites**

2'-(Aminooxyethoxy) nucleoside amidites [also known in the art as 2'-O-(aminooxyethyl) nucleoside amidites] are prepared as described in the following paragraphs. Adenosine, cytidine and thymidine nucleoside amidites are prepared similarly.

**N2-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite]**

The 2'-O-aminooxyethyl guanosine analog may be obtained by selective 2'-O-alkylation of diaminopurine riboside. Multigram quantities of diaminopurine riboside may be purchased from Schering AG (Berlin) to provide 2'-O-(2-ethylacetyl) diaminopurine riboside along with a minor amount of the 3'-O-isomer. 2'-O-(2-ethylacetyl) diaminopurine riboside may be resolved and converted to 2'-O-(2-ethylacetyl)guanosine by treatment with adenosine deaminase. (McGee, D. P. C., Cook, P. D., Guinosso, C. J., WO 94/02501 A1 940203.) Standard protection procedures should afford 2'-O-(2-ethylacetyl)-5'-O-(4,4'-

dimethoxytrityl)guanosine and 2-N-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine which may be reduced to provide 2-N-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine. As before the hydroxyl group may be displaced by N-hydroxyphthalimide via a Mitsunobu reaction, and the protected nucleoside may be phosphitylated as usual to yield 2-N-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite].

#### Example 2

##### Oligonucleotide synthesis

Unsubstituted and substituted phosphodiester (P=O) oligonucleotides are synthesized on an automated DNA synthesizer (Applied Biosystems model 380B) using standard phosphoramidite chemistry with oxidation by iodine.

Phosphorothioates (P=S) are synthesized as for the phosphodiester oligonucleotides except the standard oxidation bottle was replaced by 0.2 M solution of 3H-1,2-benzodithiole-3-one 1,1-dioxide in acetonitrile for the stepwise thiation of the phosphite linkages. The thiation wait step was increased to 68 sec and was followed by the capping step. After cleavage from the CPG column and deblocking in concentrated ammonium hydroxide at 55°C (18 h), the oligonucleotides were purified by precipitating twice with 2.5 volumes of ethanol from a 0.5 M NaCl solution. Phosphinate oligonucleotides are prepared as described in U.S. Patent 5,508,270, herein incorporated by reference.

Alkyl phosphonate oligonucleotides are prepared as described in U.S. Patent 4,469,863, herein incorporated by reference.

3'-Deoxy-3'-methylene phosphonate oligonucleotides are prepared as described in U.S. Patents 5,610,289 or

5,625,050, herein incorporated by reference.

Phosphoramidite oligonucleotides are prepared as described in U.S. Patent, 5,256,775 or U.S. Patent 5,366,878, herein incorporated by reference.

5 Alkylphosphonothioate oligonucleotides are prepared as described in published PCT applications PCT/US94/00902 and PCT/US93/06976 (published as WO 94/17093 and WO 94/02499, respectively), herein incorporated by reference.

10 3'-Deoxy-3'-amino phosphoramidate oligonucleotides are prepared as described in U.S. Patent 5,476,925, herein incorporated by reference.

Phosphotriester oligonucleotides are prepared as described in U.S. Patent 5,023,243, herein incorporated by reference.

15 Borano phosphate oligonucleotides are prepared as described in U.S. Patents 5,130,302 and 5,177,198, both herein incorporated by reference.

### **Example 3**

#### **Oligonucleoside Synthesis**

20 Methylenemethylimino linked oligonucleosides, also identified as MMI linked oligonucleosides, methylenedimethylhydrazo linked oligonucleosides, also identified as MDH linked oligonucleosides, and methylenecarbonylamino linked oligonucleosides, also identified as amide-3 linked  
25 oligonucleosides, and methyleneaminocarbonyl linked oligonucleosides, also identified as amide-4 linked oligonucleosides, as well as mixed backbone compounds having, for instance, alternating MMI and P=O or P=S linkages are prepared as described in U.S. Patents 5,378,825, 5,386,023,  
30 5,489,677, 5,602,240 and 5,610,289, all of which are herein incorporated by reference.

Formacetal and thioformacetal linked oligonucleosides are prepared as described in U.S. Patents 5,264,562 and 5,264,564, herein incorporated by reference.

35 Ethylene oxide linked oligonucleosides are prepared as

described in U.S. Patent 5,223,618, herein incorporated by reference.

#### **Example 4**

##### **PNA Synthesis**

5       Peptide nucleic acids (PNAs) are prepared in accordance with any of the various procedures referred to in Peptide Nucleic Acids (PNA): Synthesis, Properties and Potential Applications, *Bioorganic & Medicinal Chemistry*, 1996, 4, 5-23. They may also be prepared in accordance  
10       with U.S. Patents 5,539,082, 5,700,922, and 5,719,262, herein incorporated by reference.

#### **Example 5**

##### **Synthesis of Chimeric Oligonucleotides**

Chimeric oligonucleotides, oligonucleosides or mixed  
15       oligonucleotides/oligonucleosides of the invention can be of several different types. These include a first type wherein the "gap" segment of linked nucleosides is positioned between 5' and 3' "wing" segments of linked nucleosides and a second "open end" type wherein the "gap"  
20       segment is located at either the 3' or the 5' terminus of the oligomeric compound. Oligonucleotides of the first type are also known in the art as "gapmers" or gapped oligonucleotides. Oligonucleotides of the second type are also known in the art as "hemimers" or "wingmers".

##### **25       [2'-O-Me]--[2'-deoxy]--[2'-O-Me] Chimeric Phosphorothioate Oligonucleotides**

Chimeric oligonucleotides having 2'-O-alkyl phosphorothioate and 2'-deoxy phosphorothioate oligonucleotide segments are synthesized using an Applied  
30       Biosystems automated DNA synthesizer Model 380B, as above. Oligonucleotides are synthesized using the automated synthesizer and 2'-deoxy-5'-dimethoxytrityl-3'-O-phosphoramidite for the DNA portion and 5'-dimethoxytrityl-2'-O-methyl-3'-O-phosphoramidite for 5' and 3' wings. The



standard synthesis cycle is modified by increasing the wait step after the delivery of tetrazole and base to 600 s repeated four times for RNA and twice for 2'-O-methyl. The fully protected oligonucleotide is cleaved from the support and the phosphate group is deprotected in 3:1 ammonia/ethanol at room temperature overnight then lyophilized to dryness. Treatment in methanolic ammonia for 24 hrs at room temperature is then done to deprotect all bases and sample was again lyophilized to dryness. The pellet is resuspended in 1M TBAF in THF for 24 hrs at room temperature to deprotect the 2' positions. The reaction is then quenched with 1M TEAA and the sample is then reduced to 1/2 volume by rotovac before being desalted on a G25 size exclusion column. The oligo recovered is then analyzed spectrophotometrically for yield and for purity by capillary electrophoresis and by mass spectrometry.

**[2'-O-(2-Methoxyethyl)]--[2'-deoxy]--[2'-O-(Methoxyethyl)] Chimeric Phosphorothioate Oligonucleotides**

[2'-O-(2-methoxyethyl)]--[2'-deoxy]--[2'-O-(methoxyethyl)] chimeric phosphorothioate oligonucleotides were prepared as per the procedure above for the 2'-O-methyl chimeric oligonucleotide, with the substitution of 2'-O-(methoxyethyl) amidites for the 2'-O-methyl amidites.

**[2'-O-(2-Methoxyethyl)Phosphodiester]--[2'-deoxy Phosphorothioate]--[2'-O-(2-Methoxyethyl) Phosphodiester] Chimeric Oligonucleotides**

[2'-O-(2-methoxyethyl phosphodiester)]--[2'-deoxy phosphorothioate]--[2'-O-(methoxyethyl) phosphodiester] chimeric oligonucleotides are prepared as per the above procedure for the 2'-O-methyl chimeric oligonucleotide with the substitution of 2'-O-(methoxyethyl) amidites for the 2'-O-methyl amidites, oxidization with iodine to generate the phosphodiester internucleotide linkages within the

wing portions of the chimeric structures and sulfurization utilizing 3,4-dihydro-2H-benzodithiole-3-one 1,1-dioxide (Beaucage Reagent) to generate the phosphorothioate internucleotide linkages for the center gap.

- 5 Other chimeric oligonucleotides, chimeric oligonucleosides and mixed chimeric oligonucleotides/oligonucleosides are synthesized according to United States patent 5,623,065, herein incorporated by reference.

#### **Example 6**

##### **10 Oligonucleotide Isolation**

- After cleavage from the controlled pore glass column (Applied Biosystems) and deblocking in concentrated ammonium hydroxide at 55°C for 18 hours, the oligonucleotides or oligonucleosides are purified by
- 15 precipitation twice out of 0.5 M NaCl with 2.5 volumes ethanol. Synthesized oligonucleotides were analyzed by polyacrylamide gel electrophoresis on denaturing gels and judged to be at least 85% full length material. The relative amounts of phosphorothioate and phosphodiester
- 20 linkages obtained in synthesis were periodically checked by <sup>31</sup>P nuclear magnetic resonance spectroscopy, and for some studies oligonucleotides were purified by HPLC, as described by Chiang et al., *J. Biol. Chem.* **1991**, 266, 18162-18171. Results obtained with HPLC-purified material
- 25 were similar to those obtained with non-HPLC purified material.

#### **Example 7**

##### **Oligonucleotide Synthesis - 96 Well Plate Format**

- Oligonucleotides were synthesized via solid phase
- 30 P(III) phosphoramidite chemistry on an automated synthesizer capable of assembling 96 sequences simultaneously in a standard 96 well format. Phosphodiester internucleotide linkages were afforded by oxidation with aqueous iodine. Phosphorothioate

internucleotide linkages were generated by sulfurization utilizing 3,4-dihydro-2H-benzothio-1,2-dioxole-3-one 1,1-dioxide (Beaucage Reagent) in anhydrous acetonitrile. Standard base-protected beta-cyanoethyl-diisopropyl phosphoramidites were purchased from commercial vendors (e.g. PE-Applied Biosystems, Foster City, CA, or Pharmacia, Piscataway, NJ). Non-standard nucleosides are synthesized as per known literature or patented methods. They are utilized as base-protected beta-cyanoethyl-diisopropyl phosphoramidites.

Oligonucleotides were cleaved from support and deprotected with concentrated  $\text{NH}_4\text{OH}$  at elevated temperature (55-60°C) for 12-16 hours and the released product then dried in vacuo. The dried product was then re-suspended in sterile water to afford a master plate from which all analytical and test plate samples are then diluted utilizing robotic pipettors.

#### **Example 8**

##### **Oligonucleotide Analysis - 96 Well Plate Format**

The concentration of oligonucleotide in each well was assessed by dilution of samples and UV absorption spectroscopy. The full-length integrity of the individual products was evaluated by capillary electrophoresis (CE) in either the 96 well format (Beckman P/ACE™ MDQ) or, for individually prepared samples, on a commercial CE apparatus (e.g., Beckman P/ACE™ 5000, ABI 270). Base and backbone composition was confirmed by mass analysis of the compounds utilizing electrospray-mass spectroscopy. All assay test plates were diluted from the master plate using single and multi-channel robotic pipettors. Plates were judged to be acceptable if at least 85% of the compounds on the plate were at least 85% full length.

#### **Example 9**

##### **Cell culture and oligonucleotide treatment**

The effect of antisense compounds on target nucleic acid expression can be tested in any of a variety of cell

types provided that the target nucleic acid is present at measurable levels. This can be routinely determined using, for example, PCR or Northern blot analysis. The following four cell types are provided for illustrative purposes, but  
5 other cell types can be routinely used.

T-24 cells:

The transitional cell bladder carcinoma cell line T-24 was obtained from the American Type Culture Collection (ATCC) (Manassas, VA). T-24 cells were routinely cultured  
10 in complete McCoy's 5A basal media (Gibco/Life Technologies, Gaithersburg, MD) supplemented with 10% fetal calf serum (Gibco/Life Technologies, Gaithersburg, MD), penicillin 100 units per mL, and streptomycin 100  
15 micrograms per mL (Gibco/Life Technologies, Gaithersburg, MD). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence. Cells were seeded into 96-well plates (Falcon-Primaria #3872) at a density of 7000 cells/well for use in RT-PCR analysis.

For Northern blotting or other analysis, cells may be  
20 seeded onto 100 mm or other standard tissue culture plates and treated similarly, using appropriate volumes of medium and oligonucleotide.

A549 cells:

The human lung carcinoma cell line A549 was obtained  
25 from the American Type Culture Collection (ATCC) (Manassas, VA). A549 cells were routinely cultured in DMEM basal media (Gibco/Life Technologies, Gaithersburg, MD) supplemented with 10% fetal calf serum (Gibco/Life Technologies, Gaithersburg, MD), penicillin 100 units per  
30 mL, and streptomycin 100 micrograms per mL (Gibco/Life Technologies, Gaithersburg, MD). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence.

NHDF cells:

35 Human neonatal dermal fibroblast (NHDF) were obtained

-67-

from the Clonetics Corporation (Walkersville MD). NHDFs were routinely maintained in Fibroblast Growth Medium (Clonetics Corporation, Walkersville MD) supplemented as recommended by the supplier. Cells were maintained for up to 10 passages as recommended by the supplier.

HEK cells:

Human embryonic keratinocytes (HEK) were obtained from the Clonetics Corporation (Walkersville MD). HEKs were routinely maintained in Keratinocyte Growth Medium (Clonetics Corporation, Walkersville MD) formulated as recommended by the supplier. Cells were routinely maintained for up to 10 passages as recommended by the supplier.

Treatment with antisense compounds:

When cells reached 80% confluency, they were treated with oligonucleotide. For cells grown in 96-well plates, wells were washed once with 200  $\mu$ L OPTI-MEM™-1 reduced-serum medium (Gibco BRL) and then treated with 130  $\mu$ L of OPTI-MEM™-1 containing 3.75  $\mu$ g/mL LIPOFECTIN™ (Gibco BRL) and the desired oligonucleotide at a final concentration of 150 nM. After 4 hours of treatment, the medium was replaced with fresh medium. Cells were harvested 16 hours after oligonucleotide treatment.

#### **Example 10**

#### **Analysis of oligonucleotide inhibition of Cellular Inhibitor of Apoptosis-1 expression**

Antisense modulation of Cellular Inhibitor of Apoptosis-1 expression can be assayed in a variety of ways known in the art. For example, Cellular Inhibitor of Apoptosis-1 mRNA levels can be quantitated by, e.g., Northern blot analysis, competitive polymerase chain reaction (PCR), or real-time PCR (RT-PCR). Real-time quantitative PCR is presently preferred. RNA analysis can be performed on total cellular RNA or poly(A)+ mRNA. Methods of RNA isolation are taught in, for example,

-68-

Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 1, pp. 4.1.1-4.2.9 and 4.5.1-4.5.3, John Wiley & Sons, Inc., 1993. Northern blot analysis is routine in the art and is taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 1, pp. 4.2.1-4.2.9, John Wiley & Sons, Inc., 1996. Real-time quantitative (PCR) can be conveniently accomplished using the commercially available ABI PRISM™ 7700 Sequence Detection System, available from PE-Applied Biosystems, Foster City, CA and used according to manufacturer's instructions. Other methods of PCR are also known in the art.

Cellular Inhibitor of Apoptosis-1 protein levels can be quantitated in a variety of ways well known in the art, such as immunoprecipitation, Western blot analysis (immunoblotting), ELISA or fluorescence-activated cell sorting (FACS). Antibodies directed to Cellular Inhibitor of Apoptosis-1 can be identified and obtained from a variety of sources, such as the MSRS catalog of antibodies (Aerie Corporation, Birmingham, MI), or can be prepared via conventional antibody generation methods. Methods for preparation of polyclonal antisera are taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 11.12.1-11.12.9, John Wiley & Sons, Inc., 1997. Preparation of monoclonal antibodies is taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 11.4.1-11.11.5, John Wiley & Sons, Inc., 1997.

Immunoprecipitation methods are standard in the art and can be found at, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 10.16.1-10.16.11, John Wiley & Sons, Inc., 1998. Western blot (immunoblot) analysis is standard in the art and can be found at, for example, Ausubel, F.M. et al., *Current*

*Protocols in Molecular Biology*, Volume 2, pp. 10.8.1-10.8.21, John Wiley & Sons, Inc., 1997. Enzyme-linked immunosorbent assays (ELISA) are standard in the art and can be found at, for example, Ausubel, F.M. et al., *Current*  
5 *Protocols in Molecular Biology*, Volume 2, pp. 11.2.1-11.2.22, John Wiley & Sons, Inc., 1991.

#### **Example 11**

##### **Poly(A)+ mRNA isolation**

Poly(A)+ mRNA was isolated according to Miura et al.,  
10 *Clin. Chem.*, 1996, 42, 1758-1764. Other methods for poly(A)+ mRNA isolation are taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 1, pp. 4.5.1-4.5.3, John Wiley & Sons, Inc., 1993. Briefly, for cells grown on 96-well plates,  
15 growth medium was removed from the cells and each well was washed with 200  $\mu$ L cold PBS. 60  $\mu$ L lysis buffer (10 mM Tris-HCl, pH 7.6, 1 mM EDTA, 0.5 M NaCl, 0.5% NP-40, 20 mM vanadyl-ribonucleoside complex) was added to each well, the plate was gently agitated and then incubated at room  
20 temperature for five minutes. 55  $\mu$ L of lysate was transferred to Oligo d(T) coated 96-well plates (AGCT Inc., Irvine CA). Plates were incubated for 60 minutes at room temperature, washed 3 times with 200  $\mu$ L of wash buffer (10 mM Tris-HCl pH 7.6, 1 mM EDTA, 0.3 M NaCl). After the  
25 final wash, the plate was blotted on paper towels to remove excess wash buffer and then air-dried for 5 minutes. 60  $\mu$ L of elution buffer (5 mM Tris-HCl pH 7.6), preheated to 70°C was added to each well, the plate was incubated on a 90°C hot plate for 5 minutes, and the eluate was then  
30 transferred to a fresh 96-well plate.

Cells grown on 100 mm or other standard plates may be treated similarly, using appropriate volumes of all solutions.

**Example 12****Total RNA Isolation**

Total mRNA was isolated using an RNEASY 96™ kit and buffers purchased from Qiagen Inc. (Valencia CA) following the manufacturer's recommended procedures. Briefly, for cells grown on 96-well plates, growth medium was removed from the cells and each well was washed with 200 µL cold PBS. 100 µL Buffer RLT was added to each well and the plate vigorously agitated for 20 seconds. 100 µL of 70% ethanol was then added to each well and the contents mixed by pipetting three times up and down. The samples were then transferred to the RNEASY 96™ well plate attached to a QIAVAC™ manifold fitted with a waste collection tray and attached to a vacuum source. Vacuum was applied for 15 seconds. 1 mL of Buffer RW1 was added to each well of the RNEASY 96™ plate and the vacuum again applied for 15 seconds. 1 mL of Buffer RPE was then added to each well of the RNEASY 96™ plate and the vacuum applied for a period of 15 seconds. The Buffer RPE wash was then repeated and the vacuum was applied for an additional 10 minutes. The plate was then removed from the QIAVAC™ manifold and blotted dry on paper towels. The plate was then re-attached to the QIAVAC™ manifold fitted with a collection tube rack containing 1.2 mL collection tubes. RNA was then eluted by pipetting 60 µL water into each well, incubating 1 minute, and then applying the vacuum for 30 seconds. The elution step was repeated with an additional 60 µL water.

**Example 13****Real-time Quantitative PCR Analysis of Cellular Inhibitor of Apoptosis-1 mRNA Levels**

Quantitation of Cellular Inhibitor of Apoptosis-1 mRNA levels was determined by real-time quantitative PCR using the ABI PRISM™ 7700 Sequence Detection System (PE-Applied Biosystems, Foster City, CA) according to manufacturer's



-71-

instructions. This is a closed-tube, non-gel-based, fluorescence detection system which allows high-throughput quantitation of polymerase chain reaction (PCR) products in real-time. As opposed to standard PCR, in which amplification products are quantitated after the PCR is completed, products in real-time quantitative PCR are quantitated as they accumulate. This is accomplished by including in the PCR reaction an oligonucleotide probe that anneals specifically between the forward and reverse PCR primers, and contains two fluorescent dyes. A reporter dye (e.g., JOE or FAM, obtained from either Operon Technologies Inc., Alameda, CA or PE-Applied Biosystems, Foster City, CA) is attached to the 5' end of the probe and a quencher dye (e.g., TAMRA, obtained from either Operon Technologies Inc., Alameda, CA or PE-Applied Biosystems, Foster City, CA) is attached to the 3' end of the probe. When the probe and dyes are intact, reporter dye emission is quenched by the proximity of the 3' quencher dye. During amplification, annealing of the probe to the target sequence creates a substrate that can be cleaved by the 5'-exonuclease activity of Taq polymerase. During the extension phase of the PCR amplification cycle, cleavage of the probe by Taq polymerase releases the reporter dye from the remainder of the probe (and hence from the quencher moiety) and a sequence-specific fluorescent signal is generated. With each cycle, additional reporter dye molecules are cleaved from their respective probes, and the fluorescence intensity is monitored at regular (six-second) intervals by laser optics built into the ABI PRISM™ 7700 Sequence Detection System. In each assay, a series of parallel reactions containing serial dilutions of mRNA from untreated control samples generates a standard curve that is used to quantitate the percent inhibition after antisense oligonucleotide treatment of test samples.

PCR reagents were obtained from PE-Applied Biosystems,

Foster City, CA. RT-PCR reactions were carried out by adding 25  $\mu$ L PCR cocktail (1x TAQMAN<sup>™</sup> buffer A, 5.5 mM MgCl<sub>2</sub>, 300  $\mu$ M each of dATP, dCTP and dGTP, 600  $\mu$ M of dUTP, 100 nM each of forward primer, reverse primer, and probe, 5 20 Units RNase inhibitor, 1.25 Units AMPLITAQ GOLD<sup>™</sup>, and 12.5 Units MuLV reverse transcriptase) to 96 well plates containing 25  $\mu$ L poly(A) mRNA solution. The RT reaction was carried out by incubation for 30 minutes at 48°C. Following a 10 minute incubation at 95°C to activate the 10 AMPLITAQ GOLD<sup>™</sup>, 40 cycles of a two-step PCR protocol were carried out: 95°C for 15 seconds (denaturation) followed by 60°C for 1.5 minutes (annealing/extension). Cellular Inhibitor of Apoptosis-1 probes and primers were designed to hybridize to the human Cellular Inhibitor of Apoptosis-1 15 sequence, using published sequence information (GenBank accession number U37547, incorporated herein as SEQ ID NO:1).

For Cellular Inhibitor of Apoptosis-1 the PCR primers were:

20 forward primer: TGCCTGTGGTGGGAAGCT (SEQ ID NO: 2)  
reverse primer: GGAAATGCCTCCGGTGTT (SEQ ID NO: 3) and the  
PCR probe was: FAM-TAACTGGGAACCAAAGGATGATGCTATGTCA-TAMRA  
(SEQ ID NO: 4) where FAM (PE-Applied Biosystems, Foster  
City, CA) is the fluorescent reporter dye) and TAMRA (PE-  
25 Applied Biosystems, Foster City, CA) is the quencher dye.

For GAPDH the PCR primers were:

forward primer: GAAGGTGAAGGTCGGAGTC (SEQ ID NO: 5)  
reverse primer: GAAGATGGTGATGGGATTTC (SEQ ID NO: 6) and the  
PCR probe was: 5' JOE-CAAGCTTCCCGTTCTCAGCC- TAMRA 3' (SEQ  
30 ID NO: 7) where JOE (PE-Applied Biosystems, Foster City,  
CA) is the fluorescent reporter dye) and TAMRA (PE-Applied  
Biosystems, Foster City, CA) is the quencher dye.

**Example 14****Northern blot analysis of Cellular Inhibitor of Apoptosis-1 mRNA levels**

Eighteen hours after antisense treatment, cell  
5 monolayers were washed twice with cold PBS and lysed in 1  
mL RNAZOL™ (TEL-TEST "B" Inc., Friendswood, TX). Total RNA  
was prepared following manufacturer's recommended  
protocols. Twenty micrograms of total RNA was fractionated  
10 by electrophoresis through 1.2% agarose gels containing  
1.1% formaldehyde using a MOPS buffer system (AMRESCO, Inc.  
Solon, OH). RNA was transferred from the gel to HYBOND™-N+  
nylon membranes (Amersham Pharmacia Biotech, Piscataway,  
NJ) by overnight capillary transfer using a  
Northern/Southern Transfer buffer system (TEL-TEST "B"  
15 Inc., Friendswood, TX). RNA transfer was confirmed by UV  
visualization. Membranes were fixed by UV cross-linking  
using a STRATALINKER™ UV Crosslinker 2400 (Stratagene,  
Inc, La Jolla, CA).

Membranes were probed using QUICKHYB™ hybridization  
20 solution (Stratagene, La Jolla, CA) using manufacturer's  
recommendations for stringent conditions with a Cellular  
Inhibitor of Apoptosis-1 specific probe prepared by PCR  
using the forward primer TGCCTGTGGTGGGAAGCT (SEQ ID NO: 2)  
and the reverse primer GGAAAATGCCTCCGGTGTT (SEQ ID NO: 3).  
25 To normalize for variations in loading and transfer  
efficiency membranes were stripped and probed for  
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) RNA  
(Clontech, Palo Alto, CA). Hybridized membranes were  
visualized and quantitated using a PHOSPHORIMAGER™ and  
30 IMAGEQUANT™ Software V3.3 (Molecular Dynamics, Sunnyvale,  
CA). Data was normalized to GAPDH levels in untreated  
controls.

**Example 15****Antisense inhibition of Cellular Inhibitor of Apoptosis-1 expression- phosphorothioate oligodeoxynucleotides**

In accordance with the present invention, a series of  
 5 oligonucleotides were designed to target different regions  
 of the human Cellular Inhibitor of Apoptosis-1 RNA, using  
 published sequences (GenBank accession number U37547,  
 incorporated herein as SEQ ID NO: 1). The oligonucleotides  
 are shown in Table 1. Target sites are indicated by  
 10 nucleotide numbers, as given in the sequence source  
 reference (Genbank accession no. U37547), to which the  
 oligonucleotide binds. All compounds in Table 1 are  
 oligodeoxynucleotides with phosphorothioate backbones  
 (internucleoside linkages) throughout. The compounds were  
 15 analyzed for effect on Cellular Inhibitor of Apoptosis-1  
 mRNA levels by quantitative real-time PCR as described in  
 other examples herein. Data are averages from three  
 experiments. If present, "N.D." indicates "no data".

Table 1

20 Inhibition of Cellular Inhibitor of Apoptosis-1 mRNA levels  
 by phosphorothioate oligodeoxynucleotides

	ISIS#	REGION	TARGET SITE	SEQUENCE	% Inhibition	SEQ ID NO.
	23332	5' UTR	4	aaattacactccatagaa	0	8
25	23333	5' UTR	68	aatcaactctactagcct	47	9
	23334	5' UTR	139	ctagtgttatcagaaacg	0	10
	23335	5' UTR	216	ttaaggactattcagcta	0	11
	23336	5' UTR	287	ttagttagccataaaaatt	0	12
	23337	5' UTR	352	actttcttcctaactttg	0	13
30	23338	5' UTR	435	ttggcttaaagttcaaaa	0	14
	23339	5' UTR	497	aagtcaatacccacaagc	0	15
	23340	5' UTR	576	aaaagctaagttcacaca	0	16
	23341	5' UTR	661	aagcactttaacatgaca	15	17
	23342	5' UTR	684	tatatgcaggcttctttc	23	18
35	23343	5' UTR	724	ataacagaccaattactg	0	19
	23344	5' UTR	764	tgctttttatttatattt	0	20
	23345	5' UTR	858	aggtggatgcacttctga	0	21
	23346	5' UTR	915	ggtaacctaaagtgcatt	0	22

-75-

	23347	5' UTR	994	tcaggtaggatgagtatc	11	23
	23348	5' UTR	1097	tttcttcacatgaactaa	0	24
	23349	Coding	1178	acctgggaaaagtctttg	0	25
	23350	Coding	1234	caatctgacaagatcgtg	0	26
5	23351	Coding	1285	tagagttcacaggaaaag	0	27
	23352	Coding	1491	ccagattctgaataaagc	0	28
	23353	Coding	1540	tttctcattggagacgta	32	29
	23354	Coding	1572	ccaaggtgggagataatg	3	30
	23355	Coding	1603	gagtaagaaccactgaac	0	31
10	23356	Coding	1632	tagaattaagagggtttg	0	32
	23357	Coding	1717	tggtaggtgaagaaatctg	0	33
	23358	Coding	1835	ttcccagttactgagctt	78	34
	23359	Coding	1936	ctcagatttgaaatgcta	0	35
	23360	Coding	2093	ttcccaacacctcaagcc	55	36
15	23361	Coding	2193	taccttgaatctcatcaa	0	37
	23362	Coding	2269	ataattgggtgggtcagca	0	38
	23363	Coding	2391	ttttactttgaactgttt	0	39
	23364	Coding	2501	catttcttcagcttggtt	0	40
	23365	Coding	2661	tcgcttgtaaaggatatct	0	41
20	23366	Coding	2774	attcttatccacaaataa	0	42
	23367	Coding	2904	gaccacaaggaataaata	0	43
	23368	3' UTR	3071	ttagatggcttcaagtgt	10	44
	23369	3' UTR	3222	atatagttcaccaaaca	0	45
	23370	3' UTR	3355	ttcctgggtttccagttct	46	46
25	23371	3' UTR	3407	agtgaaaagcaccaaaga	0	47

As shown in Table 1, SEQ ID NOs 9, 18, 29, 34, 36 and 46 demonstrated at least 20% inhibition of Cellular Inhibitor of Apoptosis-1 expression in this assay and are therefore preferred.

#### Example 16:

#### Antisense inhibition of Cellular Inhibitor of Apoptosis-1 expression- phosphorothioate 2'-MOE gapmer oligonucleotides

In accordance with the present invention, a second series of oligonucleotides targeted to human Cellular Inhibitor of Apoptosis-1 were synthesized. The oligonucleotide sequences are shown in Table 2. Target sites are indicated by nucleotide numbers, as given in the sequence source reference (Genbank accession no. U37547), to which the oligonucleotide binds.

All compounds in Table 2 are chimeric oligonucleotides ("gapmers") 18 nucleotides in length, composed of a central "gap" region consisting of ten 2'-deoxynucleotides, which is flanked on both sides (5' and 3' directions) by four-nucleotide "wings". The wings are composed of 2'-methoxyethyl (2'-MOE)nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. Cytidine residues in the 2'-MOE wings are 5-methylcytidines.

Data were obtained by real-time quantitative PCR as described in other examples herein and are averaged from three experiments. If present, "N.D." indicates "no data".

Table 2

Inhibition of Cellular Inhibitor of Apoptosis-1 mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap

	ISIS#	REGION	TARGET SITE	SEQUENCE	% Inhibition	SEQ ID NO.
	23372	5' UTR	4	aaattacactccatagaa	0	8
20	23373	5' UTR	68	aatcaactctactagcct	3	9
	23374	5' UTR	139	ctagtgttatcagaaacg	36	10
	23375	5' UTR	216	ttaaggactattcagcta	18	11
	23376	5' UTR	287	ttagttagccataaaatt	0	12
	23377	5' UTR	352	actttcttcctaactttg	0	13
25	23378	5' UTR	435	ttggcttaaagttcaaaa	6	14
	23379	5' UTR	497	aagtcaatacccacaagc	46	15
	23380	5' UTR	576	aaaagctaagttcacaca	0	16
	23381	5' UTR	661	aagcactttaacatgaca	31	17
	23382	5' UTR	684	tatatgcaggcttctttc	22	18
30	23383	5' UTR	724	ataacagaccaattactg	0	19
	23384	5' UTR	764	tgctttttattttatattt	0	20
	23385	5' UTR	858	aggtggatgcacttctga	76	21
	23386	5' UTR	915	ggtaacctaaagtgtctatt	74	22
	23387	5' UTR	994	tcaggtaggatgagtatc	40	23
35	23388	5' UTR	1097	tttcttcacatgaactaa	0	24
	23389	Coding	1178	acctgggaaaagtctttg	73	25
	23390	Coding	1234	caatctgacaagatcgtg	69	26
	23391	Coding	1285	tagagttcacaggaaaag	16	27
	23392	Coding	1491	ccagattctgaataaagc	41	28

-77-

	23393	Coding	1540	tttctcattggagacgta	70	29
	23394	Coding	1572	ccaaggtgggagataatg	22	30
	23395	Coding	1603	gagtaagaaccactgaac	8	31
	23396	Coding	1632	tagaattaagagggttg	0	32
5	23397	Coding	1717	tggtaggtaagaaatctg	50	33
	23398	Coding	1835	ttcccagttactgagctt	44	34
	23399	Coding	1936	ctcagatttgaaatgcta	51	35
	23400	Coding	2093	ttcccaacacctcaagcc	0	36
	23401	Coding	2193	taccttgaatctcatcaa	34	37
10	23402	Coding	2269	ataattgggtgggtcagca	27	38
	23403	Coding	2391	ttttactttgaactgttt	20	39
	23404	Coding	2501	catttcttcagcttggtt	12	40
	23405	Coding	2661	tcgcttgtaaaggatatct	56	41
	23406	Coding	2774	attcttatccacaaataa	0	42
15	23407	Coding	2904	gaccacaaggaataaata	0	43
	23408	3' UTR	3071	ttagatggccttcaagtgt	56	44
	23409	3' UTR	3222	atatagttcaccaaacat	35	45
	23410	3' UTR	3355	ttcctggtttccagttct	67	46
20	23411	3' UTR	3407	agtgaaaagcaccaaaga	0	47

As shown in Table 2, SEQ ID NOs 10, 15, 17, 21, 22, 23, 25, 26, 28, 29, 33, 34, 35, 37, 38, 41, 44, 45 and 46 demonstrated at least 25% inhibition of Cellular Inhibitor of Apoptosis-1 expression in this experiment and are therefore preferred.

#### Example 17

#### Western blot analysis of Cellular Inhibitor of Apoptosis-1 protein levels

Western blot analysis (immunoblot analysis) is carried out using standard methods. Cells are harvested 16-20 h after oligonucleotide treatment, washed once with PBS, suspended in Laemmli buffer (100 ul/well), boiled for 5 minutes and loaded on a 16% SDS-PAGE gel. Gels are run for 1.5 hours at 150 V, and transferred to membrane for western blotting. Appropriate primary antibody directed to Cellular Inhibitor of Apoptosis-1 is used, with a radiolabelled or fluorescently labeled secondary antibody

directed against the primary antibody species. Bands are visualized using a PHOSPHORIMAGER™ (Molecular Dynamics, Sunnyvale CA).



**What is claimed is:**

1. An antisense compound 8 to 30 nucleotides in length targeted to a nucleic acid molecule encoding human Cellular Inhibitor of Apoptosis-1, wherein said antisense compound  
5 inhibits the expression of human Cellular Inhibitor of Apoptosis-1.
2. The antisense compound of claim 1 which is an antisense oligonucleotide.
3. The antisense compound of claim 2 wherein the  
10 antisense oligonucleotide has a sequence comprising SEQ ID NO: 9, 10, 15, 17, 18, 21, 22, 23, 25, 26, 28, 29, 33, 34, 35, 36, 37, 38, 41, 44, 45 or 46.
4. The antisense compound of claim 2 wherein the antisense oligonucleotide has a sequence comprising SEQ ID NO:  
15 29, 34 or 46.
5. The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.
6. The antisense compound of claim 5 wherein the  
20 modified internucleoside linkage is a phosphorothioate linkage.
7. The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.
- 25 8. The antisense compound of claim 7 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.
9. The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.
- 30 10. The antisense compound of claim 9 wherein the modified nucleobase is a 5-methylcytosine.
11. The antisense compound of claim 1 wherein the antisense oligonucleotide is a chimeric oligonucleotide.
12. A pharmaceutical composition comprising the  
35 antisense compound of claim 1 and a pharmaceutically

-80-

acceptable carrier or diluent.

13. The pharmaceutical composition of claim 12 further comprising a colloidal dispersion system.

14. The pharmaceutical composition of claim 12 wherein  
5 the antisense compound is an antisense oligonucleotide.

15. A method of inhibiting the expression of Cellular Inhibitor of Apoptosis-1 in human cells or tissues comprising contacting said cells or tissues with the antisense compound of claim 1 so that expression of Cellular Inhibitor of  
10 Apoptosis-1 is inhibited.

16. A method of treating a human having a disease or condition associated with Cellular Inhibitor of Apoptosis-1 comprising administering to said animal a therapeutically or prophylactically effective amount of the antisense compound  
15 of claim 1 so that expression of Cellular Inhibitor of Apoptosis-1 is inhibited.

17. The method of claim 16 wherein the disease or condition is a hyperproliferative condition or autoimmune disease.

20. 18. The method of claim 17 wherein the hyperproliferative condition is cancer.

## SEQUENCE LISTING

<110> C. Frank Bennett  
Elizabeth J. Ackermann  
Lex M. Cowser

<120> ANTISENSE MODULATION OF CELLULAR INHIBITOR OF APOPTOSIS-1  
EXPRESSION

<130> ISPH-0361

<160> 47

<210> 1  
<211> 3532  
<212> DNA  
<213> Homo sapiens

<220>  
<221> CDS  
<222> (1160)..(3016)

<400> 1  
gaattctatg gagtgttaatt ttgtgtatga attatatattt taaaacattg aagagttttc 60  
agaaagaagg ctagtagagt tgattactga tactttatgc taagcagtagc ttttttggtta 120  
gtacaatatt ttgttaggcg tttctgataa cactagaaaag gacaagtttt atcttgtgat 180  
aaattgatta atgtttacaa catgactgat aattatagct gaatagtcct taaatgatga 240  
acaggttatt tagtttttaa atgcagtgtg aaaagtggtg tgtggaaatt ttatggctaa 300  
ctaagtttat ggagaaaata ccttcagttg atcaagaata atagtggat acaaagttag 360  
gaagaaagtc aacatgatgc tgcaggaaat ggaaacaaat acaaagata ttaacaaag 420  
atagagttta cagtttttga accttaagcc aaattcattt gacatcaagc actatagcag 480  
gcacaggttc aacaaagctt gtgggtattg acctttccca aaagttgtca gctgaagtaa 540

```

tttagccac ttaagtaaact actatgatga taagctgtgt gaacttagct tttaaatagt 600

gtgaccatat gaaggtttta attacttttg tttattggaa taaaatgaga ttttttgggt 660

tgtcatgtta aagtgccttat agggaaagaa gcctgcatat aattttttac cttgtggcat 720

aatcagtaat tggctctgtta ttcaggcttc atagcttgta accaaatata aataaaaaggc 780

ataatttagg tattctatag ttgcttagaa ttttgtaaat ataaatctct gtgaaaaatc 840

aaggagtttt aatattttca gaagtgcac cacctttcag ggctttaagt tagtattact 900

caagattatg aacaaatagc acttaggtta cctgaaagag ttactacaac cccaaagagt 960

tgtgttctaa gtagtatctt ggtaattcag agagatactc atcctacctg aatataaact 1020

gagataaatc cagtaaagaa agtgtagtaa attctacata agagtctatc attgatttct 1080

ttttgtggtta aaaatcttag ttcattgtgaa gaaatttcac gtgaatgttt tagctatcaa 1140

acagtactgt cacctactc atg cac aaa act gcc tcc caa aga ctt tcc 1189
                Met His Lys Thr Ala Ser Gln Arg Leu Phe
                  1             5             10

cca ggt ccc tcg tat caa aac att aag agt ata atg gaa gat agc acg 1237
Pro Gly Pro Ser Tyr Gln Asn Ile Lys Ser Ile Met Glu Asp Ser Thr
          15             20             25

atc ttg tca gat tgg aca aac agc aac aaa caa aaa atg aag tat gac 1285
Ile Leu Ser Asp Trp Thr Asn Ser Asn Lys Gln Lys Met Lys Tyr Asp
          30             35             40

ttt tcc tgt gaa ctg tac aga atg tct aca tat tca act ttc ccc gcc 1333
Phe Ser Cys Glu Leu Tyr Arg Met Ser Thr Tyr Ser Thr Phe Pro Ala
          45             50             55

ggg gtg cct gtc tca gaa agg agt ctt gct cgt gct ggt ttt tat tat 1381
Gly Val Pro Val Ser Glu Arg Ser Leu Ala Arg Ala Gly Phe Tyr Tyr
          60             65             70

act ggt gtg aat gac aag gtc aaa tgc ttc tgt tgt ggc ctg atg ctg 1429
Thr Gly Val Asn Asp Lys Val Lys Cys Phe Cys Cys Gly Leu Met Leu

```

75	80	85	90	
gat aac tgg aaa cta gga gac agt cct att caa aag cat aaa cag cta				1477
Asp Asn Trp Lys Leu Gly Asp Ser Pro Ile Gln Lys His Lys Gln Leu				
95	100	105		
tat cct agc tgt agc ttt att cag aat ctg gtt tca gct agt ctg gga				1525
Tyr Pro Ser Cys Ser Phe Ile Gln Asn Leu Val Ser Ala Ser Leu Gly				
110	115	120		
tcc acc tct aag aat acg tct cca atg aga aac agt ttt gca cat tca				1573
Ser Thr Ser Lys Asn Thr Ser Pro Met Arg Asn Ser Phe Ala His Ser				
125	130	135		
tta tct ccc acc ttg gaa cat agt agc ttg ttc agt ggt tct tac tcc				1621
Leu Ser Pro Thr Leu Glu His Ser Ser Leu Phe Ser Gly Ser Tyr Ser				
140	145	150		
agc ctt tct cca aac cct ctt aat tct aga gca gtt gaa gac atc tct				1669
Ser Leu Ser Pro Asn Pro Leu Asn Ser Arg Ala Val Glu Asp Ile Ser				
155	160	165	170	
tca tcg agg act aac ccc tac agt tat gca atg agt act gaa gaa gcc				1717
Ser Ser Arg Thr Asn Pro Tyr Ser Tyr Ala Met Ser Thr Glu Glu Ala				
175	180	185		
aga ttt ctt acc tac cat atg tgg cca tta acc ttt ttg tca cca tca				1765
Arg Phe Leu Thr Tyr His Met Trp Pro Leu Thr Phe Leu Ser Pro Ser				
190	195	200		
gaa ttg gca aga gct ggt ttt tat tat ata gga cct gga gat agg gta				1813
Glu Leu Ala Arg Ala Gly Phe Tyr Tyr Ile Gly Pro Gly Asp Arg Val				
205	210	215		
gcc tgc ttt gcc tgt ggt ggg aag ctc agt aac tgg gaa cca aag gat				1861
Ala Cys Phe Ala Cys Gly Gly Lys Leu Ser Asn Trp Glu Pro Lys Asp				
220	225	230		
gat gct atg tca gaa cac cgg agg cat ttt ccc aac tgt cca ttt ttg				1909
Asp Ala Met Ser Glu His Arg Arg His Phe Pro Asn Cys Pro Phe Leu				
235	240	245	250	

gaa aat tct cta gaa act ctg agg ttt agc att tca aat ctg agc atg	1957
Glu Asn Ser Leu Glu Thr Leu Arg Phe Ser Ile Ser Asn Leu Ser Met	
255 260 265	
cag aca cat gca gct cga atg aga aca ttt atg tac tgg cca tct agt	2005
Gln Thr His Ala Ala Arg Met Arg Thr Phe Met Tyr Trp Pro Ser Ser	
270 275 280	
gtt cca gtt cag cct gag cag ctt gca agt gct ggt ttt tat tat gtg	2053
Val Pro Val Gln Pro Glu Gln Leu Ala Ser Ala Gly Phe Tyr Tyr Val	
285 290 295	
ggc cgc aat gat gat gtc aaa tgc ttt tgt tgc gat ggt ggc ttg agg	2101
Gly Arg Asn Asp Asp Val Lys Cys Phe Cys Cys Asp Gly Gly Leu Arg	
300 305 310	
tgt tgg gaa tct gga gat gat cca tgg gta gaa cat gcc aag tgg ttt	2149
Cys Trp Glu Ser Gly Asp Asp Pro Trp Val Gln His Ala Lys Trp Phe	
315 320 325 330	
cca agg tgt gag ttc ttg ata cga atg aaa ggc caa gag ttt gtt gat	2197
Pro Arg Cys Glu Phe Leu Ile Arg Met Lys Gly Gln Glu Phe Val Asp	
335 340 345	
gag att caa ggt aga tat cct cat ctt ctt gaa cag ctg ttg tca act	2245
Glu Ile Gln Gly Arg Tyr Pro His Leu Leu Glu Gln Leu Leu Ser Thr	
350 355 360	
tca gat acc act gga gaa gaa aat gct gac cca cca att att cat ttt	2293
Ser Asp Thr Thr Gly Glu Glu Asn Ala Asp Pro Pro Ile Ile His Phe	
365 370 375	
gga cct gga gaa agt tct tca gaa gat gct gtc atg atg aat aca cct	2341
Gly Pro Gly Glu Ser Ser Ser Glu Asp Ala Val Met Met Asn Thr Pro	
380 385 390	
gtg gtt aaa tct gcc ttg gaa atg ggc ttt aat aga gac ctg gtg aaa	2389
Val Val Lys Ser Ala Leu Glu Met Gly Phe Asn Arg Asp Leu Val Lys	
395 400 405 410	
caa aca gtt caa agt aaa atc ctg aca acc gga gag aac tat aaa aca	2437
Gln Thr Val Gln Ser Lys Ile Leu Thr Thr Gly Glu Asn Tyr Lys Thr	

415	420	425	
gtt aat gat att gtg tca gca ctt ctt aat gct gaa gat gaa aaa aga			2485
Val Asn Asp Ile Val Ser Ala Leu Leu Asn Ala Glu Asp Glu Lys Arg			
430	435	440	
gaa gag gag aag gaa aaa caa gct gaa gaa atg gca tca gat gat ttg			2533
Glu Glu Glu Lys Glu Lys Gln Ala Glu Glu Met Ala Ser Asp Asp Leu			
445	450	455	
tca tta att cgg aag aac aga atg gct ctc ttt caa caa ttg aca tgt			2581
Ser Leu Ile Arg Lys Asn Arg Met Ala Leu Phe Gln Gln Leu Thr Cys			
460	465	470	
gtg ctt cct atc ctg gat aat ctt tta aag gcc aat gta att aat aaa			2629
Val Leu Pro Ile Leu Asp Asn Leu Leu Lys Ala Asn Val Ile Asn Lys			
475	480	485	490
cag gaa cat gat att att aaa caa aaa aca cag ata cct tta caa gcg			2677
Gln Glu His Asp Ile Ile Lys Gln Lys Thr Gln Ile Pro Leu Gln Ala			
495	500	505	
aga gaa ctg att gat acc att ttg gtt aaa gga aat gct gcg gcc aac			2725
Arg Glu Leu Ile Asp Thr Ile Leu Val Lys Gly Asn Ala Ala Ala Asn			
510	515	520	
atc ttc aaa aac tgt cta aaa gaa att gac tct aca ttg tat aag aac			2773
Ile Phe Lys Asn Cys Leu Lys Glu Ile Asp Ser Thr Leu Tyr Lys Asn			
525	530	535	
tta ttt gtg gat aag aat atg aag tat att cca aca gaa gat gtt tca			2821
Leu Phe Val Asp Lys Asn Met Lys Tyr Ile Pro Thr Glu Asp Val Ser			
540	545	550	
ggt ctg tca ctg gaa gaa caa ttg agg agg ttg caa gaa gaa cga act			2869
Gly Leu Ser Leu Glu Glu Gln Leu Arg Arg Leu Gln Glu Glu Arg Thr			
555	560	565	570
tgt aaa gtg tgt atg gac aaa gaa gtt tct gtt gta ttt att cct tgt			2917
Cys Lys Val Cys Met Asp Lys Glu Val Ser Val Val Phe Ile Pro Cys			
575	580	585	

ggt cat ctg gta gta tgc cag gaa tgt gcc cct tct cta aga aaa tgc 2965  
 Gly His Leu Val Val Cys Gln Glu Cys Ala Pro Ser Leu Arg Lys Cys  
 590 595 600

cct att tgc agg ggt ata atc aag ggt act gtt cgt aca ttt ctc tct 3013  
 Pro Ile Cys Arg Gly Ile Ile Lys Gly Thr Val Arg Thr Phe Leu Ser  
 605 610 615

taa agaaaaatag tctatatattt aacctgcata aaaaggctctt taaaatattg 3066

ttgaacactt gaagccatct aaagtaaaaa gggaattatg agtttttcaa ttagtaacat 3126

tcatgttcta gtctgctttg gtactaataa tcttggtttct gaaaagatgg tatcatatat 3186

ttaatcttaa tctgtttatt tacaaggga gatttatgtt tggagaacta tattagtatg 3246

tatgtgtacc taaggagta gtgtcactgc ttgttatgca tcatttcagg agttactgga 3306

tttgttgttc tttcagaaag ctttgaatac taaattatag tgtagaaaaa aactggaaac 3366

caggaactct ggagttcatc agagttatgg tgccgaattg tctttggtgc ttttcacttg 3426

tgttttaaaa taaggatttt tctcttattt ctccccctag ttgtgagaa acatctcaat 3486

aaagtgcctt ccaaaaaaaaa aaaaaagtcg acgcggccgc gaattc 3532

<210> 2  
 <211> 18  
 <212> DNA  
 <213> Artificial Sequence

<223> Synthetic

<400> 2  
 tgcctgtggt gggaagct 18

<210> 3  
 <211> 19  
 <212> DNA  
 <213> Artificial Sequence



<223> Synthetic

<400> 3

ggaaaatgcc tccggtgtt

19

<210> 4

<211> 31

<212> DNA

<213> Artificial Sequence

<223> Synthetic

<400> 4

taactgggaa ccaaaggatg atgctatgtc a

31

<210> 5

<211> 19

<212> DNA

<213> Artificial Sequence

<223> Synthetic

<400> 5

gaagggtgaag gtcggagtc

19

<210> 6

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Synthetic

<400> 6

gaagatggtg atgggatttc

20

<210> 7

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Synthetic

<400> 7

caagcttccc gttctcagcc

20

<210> 8

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Synthetic

<400> 8

aaattacact ccatagaa

18

<210> 9

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Synthetic

<400> 9

aatcaactct actagcct

18

<210> 10

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Synthetic

<400> 10

ctagtgttat cagaaacg

18

<210> 11

<211> 18  
<212> DNA  
<213> Artificial Sequence

<223> Synthetic

<400> 11  
ttaaggacta ttcagcta 18

<210> 12  
<211> 18  
<212> DNA  
<213> Artificial Sequence

<223> Synthetic

<400> 12  
ttagttagcc ataaaatt 18

<210> 13  
<211> 18  
<212> DNA  
<213> Artificial Sequence

<223> Synthetic

<400> 13  
actttcttcc taacttg 18

<210> 14  
<211> 18  
<212> DNA  
<213> Artificial Sequence

<223> Synthetic

<400> 14  
ttggcttaaa gttcaaaa 18

<210> 15  
<211> 18  
<212> DNA  
<213> Artificial Sequence

<223> Synthetic

<400> 15  
aagtcaatac ccacaagc 18

<210> 16  
<211> 18  
<212> DNA  
<213> Artificial Sequence

<223> Synthetic

<400> 16  
aaaagctaag ttcacaca 18

<210> 17  
<211> 18  
<212> DNA  
<213> Artificial Sequence

<223> Synthetic

<400> 17  
aagcacttta acatgaca 18

<210> 18  
<211> 18  
<212> DNA  
<213> Artificial Sequence

<223> Synthetic

<400> 18  
tatatgcagg·cttctttc 18

<210> 19  
<211> 18  
<212> DNA  
<213> Artificial Sequence

<223> Synthetic

<400> 19  
ataacagacc aattactg

18

<210> 20  
<211> 18  
<212> DNA  
<213> Artificial Sequence

<223> Synthetic

<400> 20  
tgccctttat ttatatatt

18

<210> 21  
<211> 18  
<212> DNA  
<213> Artificial Sequence

<223> Synthetic

<400> 21  
aggtggatgc acttctga

18

<210> 22  
<211> 18  
<212> DNA  
<213> Artificial Sequence

<223> Synthetic

<400> 22

ggtaacctaa gtgctatt

18

<210> 23

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Synthetic

<400> 23

tcaggtagga tgagtatc

18

<210> 24

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Synthetic

<400> 24

tttcttcaca tgaactaa

18

<210> 25

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Synthetic

<400> 25

acctgggaaa agtctttg

18

<210> 26

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Synthetic

<400> 26  
caatctgaca agatcgtg 18

<210> 27  
<211> 18  
<212> DNA  
<213> Artificial Sequence

<223> Synthetic

<400> 27  
tagagttcac aggaaaag 18

<210> 28  
<211> 18  
<212> DNA  
<213> Artificial Sequence

<223> Synthetic

<400> 28  
ccagattctg aataaagc 18

<210> 29  
<211> 18  
<212> DNA  
<213> Artificial Sequence

<223> Synthetic

<400> 29  
tttctcattg gagacgta 18

<210> 30  
<211> 18  
<212> DNA  
<213> Artificial Sequence

<223> Synthetic

<400> 30

ccaagggtggg agataatg

18

<210> 31

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Synthetic

<400> 31

gagtaagaac cactgaac

18

<210> 32

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Synthetic

<400> 32

tagaattaag agggtttg

18

<210> 33

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Synthetic

<400> 33

tggtaggtaa gaaatctg

18

<210> 34

<211> 18

<212> DNA



<213> Artificial Sequence

<223> Synthetic

<400> 34

ttcccagtta ctgagctt

18

<210> 35

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Synthetic

<400> 35

ctcagatttg aaatgcta

18

<210> 36

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Synthetic

<400> 36

ttcccaacac ctcaagcc

18

<210> 37

<211> 18

<212> DNA

<213> Artificial Sequence

<223> Synthetic

<400> 37

taccttgaat ctcacaa

18

<210> 38

<211> 18  
<212> DNA  
<213> Artificial Sequence

<223> Synthetic

<400> 38  
ataattggtg ggtcagca 18

<210> 39  
<211> 18  
<212> DNA  
<213> Artificial Sequence

<223> Synthetic

<400> 39  
ttttactttg aactgttt 18

<210> 40  
<211> 18  
<212> DNA  
<213> Artificial Sequence

<223> Synthetic

<400> 40  
cattttcttca gcttggtt 18

<210> 41  
<211> 18  
<212> DNA  
<213> Artificial Sequence

<223> Synthetic

<400> 41  
tcgcttgtaa aggtatct 18

<210> 42  
<211> 18  
<212> DNA  
<213> Artificial Sequence

<223> Synthetic

<400> 42  
attcttatcc acaaataa 18

<210> 43  
<211> 18  
<212> DNA  
<213> Artificial Sequence

<223> Synthetic

<400> 43  
gaccacaagg aataaata 18

<210> 44  
<211> 18  
<212> DNA  
<213> Artificial Sequence

<223> Synthetic

<400> 44  
ttagatggct tcaagtgt 18

<210> 45  
<211> 18  
<212> DNA  
<213> Artificial Sequence

<223> Synthetic

<400> 45  
atatagttca ccaaacat 18

<210> 46  
<211> 18  
<212> DNA  
<213> Artificial Sequence

<223> Synthetic

<400> 46  
ttcctggttt ccagttct

18

<210> 47  
<211> 18  
<212> DNA  
<213> Artificial Sequence

<223> Synthetic

<400> 47  
agtgaaaagc accaaaga

18

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/13624

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC(6) : C12Q 1/68; C07H 21/04; C12N 15/00 US CL : 435/6, 91.1, 375; 536/23.1, 24.31, 24.33, 24.5; 514/44 According to International Patent Classification (IPC) or to both national classification and IPC														
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) U.S. : 435/6, 91.1, 375; 536/23.1, 24.31, 24.33, 24.5; 514/44  Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) APS, Dialog: CAS, MEDLINE, BIOSIS, Derwent Biotechnology Abstracts														
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>														
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.												
A,P	BRANCH, A.A. Good antisense molecule is hard to find. TIBS. February 1998, Vol. 23, pages 45-50, see entire document.	1-18												
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.														
<table border="0"><tr><td>* Special categories of cited documents:</td><td>*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td></tr><tr><td>*A* document defining the general state of the art which is not considered to be of particular relevance</td><td>*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td></tr><tr><td>*E* earlier document published on or after the international filing date</td><td>*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td></tr><tr><td>*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td><td>*Z* document member of the same patent family</td></tr><tr><td>*O* document referring to an oral disclosure, use, exhibition or other means</td><td></td></tr><tr><td>*P* document published prior to the international filing date but later than the priority date claimed</td><td></td></tr></table>			* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	*E* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z* document member of the same patent family	*O* document referring to an oral disclosure, use, exhibition or other means		*P* document published prior to the international filing date but later than the priority date claimed	
* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention													
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone													
*E* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art													
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z* document member of the same patent family													
*O* document referring to an oral disclosure, use, exhibition or other means														
*P* document published prior to the international filing date but later than the priority date claimed														
Date of the actual completion of the international search 28 AUGUST 1999		Date of mailing of the international search report 09 SEP 1999												
Name and mailing address of the ISA-US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer: <i>John LeGuyader</i> Telephone No. (703) 308-0196												

**This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☒ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☒ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.